A CASE REPORT

Hypertensive Urgency Secondary to Tablet Retention in a Patient with Achalasia

Read Article

Achalasia is a rare disease (incidence of 1.6 cases per 100,000) that is due to degeneration of inhibitory neurons in the myenteric plexus that leads to failure of lower esophageal sphincter relaxation. It can occur at any age from childhood to old age, with both sexes equally affected. Patients complain of dysphagia of solids and liquids, non cardiac chest pain, regurgitation, weight loss and cough. Surgery is the standard of care for achalasia, but endoscopic intervention (e.g. botulinum toxin injection) can server as a temporizing measure. We report a rare case of an elderly female who presented with dysphagia, weight loss, headaches and diaphoresis and found to be in hypertensive urgency secondary to esophageal tablet retention.

Stanley Yakubov MD1 Kadirawel Iswara MD2 Ira Mayer MD2 Rabin Rahmani MD2 1Department of Medicine 2Division of Gastroenterology, Department of Medicine, Maimonides Medical Center, Brooklyn Campus of Albert Einstein College of Medicine, Brooklyn, NY

INTRODUCTION

Achalasia, meaning “failure to relax”, is a rare disease that may occur from childhood to old age, but most commonly happens between the ages of 25 and 60 with both sexes equally affected.5,6 Achalasia was initially known as cardiospasm and was treated with a sponge attached to the distal end of a carved whalebone. In 1937 Lendrum noted that the syndrome was caused by incomplete relaxation of the lower esophageal sphincter (LES) and renamed it as achalasia.1 We report a rare case of an elderly female who presented with dysphagia, weight loss, headaches and diaphoresis and found to be in hypertensive urgency secondary to esophageal tablet retention.

Case Description

An 82 year-old female with past medical history of hypertension and achalasia presented to the emergency department with severe headaches and diaphoresis. On further questioning, she reported difficulty swallowing solids and liquids and unintentional weight loss of 13 pounds over a 5-month period. Home medications included amlodipine and valsartan. On admission, her temperature was 96.7 ?F, blood pressure 207/110 mmHg, pulse 90 beats/min, respiratory rate of 20 breaths/min, and oxygen saturation of 95% on room air. Physical examination and laboratory analysis were unremarkable. Telemetry monitoring and intravenous (IV) administration of anti-hypertensive medication for presumed hypertensive urgency was instituted with subsequent improvement of her blood pressure (BP). Computed tomography of her chest and abdomen showed markedly dilated distal esophagus with fluid and debris (Figure 1). Esophagogastroduodenoscopy (EGD) revealed a fluid filled esophagus with 41 undigested tablets (Figure 2). The tablets were removed (Figure 3) using a Roth net and subsequent achalasia pneumatic balloon dilation was performed with good results. The patient was subsequently discharged from the hospital tolerating a soft diet and with significant improvement in her BP.

Discussion

Achalasia is failure of relaxation of the LES due to degeneration of inhibitory neurons in the myenteric plexus. Inhibitory neurons release nitrous oxide and vasoactive intestinal peptide neurotransmitters and cause muscle relaxation.6 It has been hypothesized that the degeneration of these inhibitory neurons in achalasia is associated with class II HLA antigen DQw1 and related to herpes and measles infection.1 Achalasia is a rare disorder with incidence of 1.6 cases per 100,000 and is about 200 fold more frequent in patients with Down syndrome.5,6 Symptoms often include dysphagia of solids and liquids, non cardiac chest pain, regurgitation, weight loss and cough.2,3 Complications include retention esophagitis, aspiration pneumonia in up to 8% of patients and esophageal squamous cell carcinoma with estimated risk ranging 30 times higher than in the general population.6 Diagnostic studies include barium swallow, endoscopy and esophageal manometry.2 Achalasia typically appears on radiographs as a dilated esophagus that terminates with a “bird beak” appearance. The therapeutic goal in achalasia is to reduce the LES pressure and allow gravity to facilitate esophageal emptying. For patients that are surgical candidates, Heller myotomy is the treatment of choice. Alternative treatment options include medications, botulinum toxin injection and endoscopic intervention. The efficacy of botulinum toxin injection at 1 month is up to 90%, but is only up to 46% at 12 months.3 After 5 years, endoscopic pneumatic dilation has a response in up to 85% of patients in retrospective study, but only in 26% in prospective study. Complications include hemorrhage in roughly 0.4% and perforation in up to 10%.6 Endoscopic balloon dilation was found to be superior to endoscopic botulinum toxin injection with better symptom relief, 68.2% vs. 40.6% respectively, and required less additional therapy, 25% vs. 46.6% respectively. Laparoscopic myotomy with fundoplication provided better symptom relief than all other surgical and endoscopic techniques, however, the overall complication rate after laparoscopic myotomy was higher than for endoscopic balloon dilatation, 6.3% vs. 1.6% respectively.4 Patients who are unable or unwilling to undergo any procedures, or in whom botulinum toxin injections fail can choose to undergo medical treatment for achalasia. Medical treatment often revolves around nitrates and calcium channel blockers as they relax the smooth muscle of LES. Studies have shown that calcium channel blockers efficacy varies greatly and is 50-90% at 6-18 month follow-up and side effects such as peripheral edema, hypotension, and headache were seen in up to 30%.3 In patients with concomitant hypertension, calcium channel blockers have the additional benefit of acting as an anti-hypertension medication.

CONCLUSION

Although EGD and balloon dilation were successful in relieving dysphagia in our patient, careful BP monitoring and periodic dysphagia questioning should be considered in all patients with achalasia and hypertension who are treated with calcium channel blockers.

Furthermore, achalasia should be considered in all individuals with dysphagia. Early recognition and treatment of achalasia will prevent complications and allow for a better quality of life.

Download Tables, Images & References

INFLAMMATORY BOWEL DISEASE: A PRACTICAL APPROACH, SERIES #9

Infection Risk Among Elderly with Inflammatory Bowel Disease

Read Article

With an aging population, the number of older patients with Crohn’s disease (CD) and ulcerative colitis (UC) and the health care costs associated with their care is expected to increase. This trend will lead to a subsequent rise in the use of immunosuppression. The risk of infection, particularly as a result of opportunistic infections in the setting of immune modifying and biologic therapy, is of utmost concern to providers and a common reason for hospitalization. In addition to medications, ongoing active intestinal inflammation, multimorbidity, malnutrition, immunosenescense, hospitalization and surgery all contribute to the predisposition to infection. Recognizing and addressing these risk factors is key to managing older IBD patients in a cost-effective manner.

BACKGROUND

The inflammatory bowel diseases (IBD), chronic inflammatory conditions of the intestine, are comprised of Crohn’s disease (CD) and ulcerative colitis (UC). Long believed to be a disease of the young, a growing number of IBD patients are over the age of 65.1 Compared to non-IBD elderly patients, the costs associated with caring for elderly IBD patients may be two fold higher.2

Unique challenges exist in the diagnosis and treatment of CD and UC in the elderly. Multimorbidities and atypical clinical presentations can cast doubt on the diagnosis. IBD management can be complicated by the patient’s functional status and polypharmacy even as the disease course may be milder when diagnosed in advanced age. Additionally, the lack of medical efficacy trials and appropriate clinical endpoints (i.e., subjective versus objective) in older IBD patients adds to the complexity of treatment decisions. One of the important considerations in the treatment of elderly patients is the development of serious infection. Multiple factors, often existing in tandem among elderly, increase the susceptibility to infection. These include ongoing active intestinal inflammation, polypharmacy, multimorbidities, poor nutrition, immunosenescence, hospitalization, and surgery. Immunosuppressive therapy, especially a combination of biologics (i.e., anti-TNF agents) and thiopurines (i.e., azathioprine, methotrexate), used to induce and maintain disease remission in adults, has been associated with an increased risk of infection and decreased response to vaccination in the elderly.3,4

The spectrum of infections in IBD is wide and can vary from uncomplicated viral upper respiratory infections to gram-negative sepsis. Strategies to prevent infection through vaccination and universal precautions are key. Early recognition and management of risk factors is significant in blunting the effect of serious infections. In a health care system moving towards tying reimbursement to quality measures, prevention of infection in elderly IBD is part of sound medical practice and important in managing costs.

Epidemiology and Cost

Between 10-30% of individuals with IBD are over the age of 60, while 10-15% are diagnosed as elderly.1,5,6 As IBD prevalence rates increase and because the disease is associated with a relatively unchanged life expectancy, the number of elderly Crohn’s disease and ulcerative colitis is expected to grow. Since many patients with IBD transition to old age with their disease, this necessitates a lifetime of care. By 2050, the US census bureau projects the expected number of elderly to double.7 Over the same time, Medicare spending will increase from 2.6% of the gross domestic product to 9.2%.8 Compared to non-IBD patients, IBD patients are seven times as likely to incur healthcare costs, five times more likely to have an outpatient clinic visit, and three times as likely to undergo an inpatient stay.2

Maintenance of disease remission in CD and UC is directly associated with improved patient outcomes and quality of life. In patients with moderate to severe active IBD, thiopurines and biologics may be the most effective options. Over the last two decades, the use of these medications has increased. While this has decreased IBD-related hospitalizations and surgeries, there has been an associated increased rate of adverse events attributable to immune suppression, namely malignancy and serious infections.10,11 Pneumonia, cellulitis, and perianal and intraabdominal abscesses are commonly cited serious infections, often leading to an inpatient stay.12 Infection-related hospitalizations of IBD inpatients are associated with longer hospital days and higher hospitalizations costs.13

Risk Factors for Serious Infections in Elderly IBD

Multiple factors influence infection risk in elderly IBD patients.Multimorbidity, polypharmacy, immunosenescence, malnutrition, immunosuppressive agents, hospitalization and surgery all play important roles. When evaluating all potential factors, active intestinal inflammation is the strongest predictor of serious infection.12 Treatment with infliximab, a biologic, is associated with a higher risk of infection in the absence of higher mortality, suggesting that the mortality rate with treatment of active disease outweighs the risks associated with the anti-TNF, including infection.12

Persistent active gut inflammation can predispose to infection. Dysbiosis, or disruption of the gut microbiota, thought to be in part associated with pathogenesis and changing disease activity in IBD,14 predisposes to Clostridium difficile infection. C. difficile colitis, much like CMV colitis, is associated with more severe IBD and may reflect incompletely controlled active inflammation.15,16 Advanced age is a well-known risk factor for the development of C. difficile infection, which in the elderly is associated with significant morbidity and mortality, accounting for a 20% readmission rate and a 9% mortality rate in hospitalized patients.17

Multimorbidity

As the prevalence of many diseases rises with age, multimorbidity becomes more prevalent over time affecting 35% of Americans over the age of 65 and 70% of those over the age of 80.18 One third of patients over 65 have four or more comorbidities and both the number and proportion of patients with multiple comorbidities is expected to grow.18,19 The resulting costs are revealing, as two-thirds of Medicare patients with multimorbidity account for 96% of Medicare expenditures.18 In elderly IBD, the most common comorbid conditions, cardiovascular illness, chronic lung disease, and diabetes,20 can increase susceptibility to complications and effect medical treatment options. Anti-TNFs, for instance, are contraindicated in New York Heart Association Class III/IV heart failure, while corticosteroids can worsen diabetes.21

Polypharmacy

Multimorbidity often requires several prescriptions, and older IBD patients take an average of 7 medications on a daily basis.20 Additionally, older patients are at increased risk for adverse events due to the changes in drug metabolism and decreased drug clearance in the elderly. In the setting of a lower glomerular filtration rate, the clearance of corticosteroids in older patients is decreased, potentiating any systemic side effects, including infection.1 Polypharmacy is associated with increased risk of drug-drug and drug-condition interactions which need to be carefully considered when managing older IBD patients. For example, antibiotic and proton pump inhibitor use can predispose to C. difficile colitis.22

Malnutrition

In IBD, malnutrition may result from small bowel resection, malabsorption, medication side effects, and changes in diet. Comorbid conditions impact the nutritional state of elderly. In one study across Europe, the United States, and South Africa, over a third of hospitalized older adults met the criteria for malnutrition.23 In active IBD, severe malnutrition affects a third of patients and serves as a risk factor for mortality in hospitalized patients.13,24 Poor nutrition is a recognized risk factor for opportunistic infections.25

Immunosenescence

While poor nutrition is associated with an impaired immune system, aging is associated with immunosenescence, a gradual deterioration of the immune system associated with impaired stem cell regeneration, neutrophil and macrophage dysfunction, altered barrier function, and decreased production of B-cells and T-cells.26-28 These changes can increase the susceptibility to infection and the persistence of infections due to an inability to clear the pathogen. The elderly have been shown to have higher rates of bacteremia and sepsis and incident rates of sepsis have increased 20% faster in elderly when compared to younger patients.29,30 In older IBD patients on immunosuppression, the risk of severe infection is greater than younger patients.3

Overall, respiratory infections, including pneumococcal pneumonia and influenza, are the most common type of infection in IBD patients. Among opportunistic infections in CD and UC, herpes zoster may be most often seen.31 Many of the common infections in IBD are vaccine-preventable and in older adults, these infections tend to have a more severe disease course.4 Nonetheless, the vaccination rates in IBD patients are suboptimal, in part because it is not a point of discussion during office visits.32 Once patients are scheduled to undergo vaccination, immune suppression therapy can reduce their efficacy. Compared to patients on monotherapy with biologics or thiopurines, adults on dual therapy have a decreased response to vaccines.4

Medications

For many providers caring for elderly IBD, the potential adverse effects secondary to immune suppression are particularly concerning. In older patients, data regarding safety of anti-TNFs is derived mainly from the rheumatology literature, where the results are mixed.33,34 In rheumatoid arthritis, infliximab at higher than standard dose (10 mg/kg) when combined with methotrexate led to more than a threefold increased risk of serious infection compared to those who received methotrexate alone (P = 0.013).35 In IBD patients, a large retrospective study evaluating the use of infliximab and adalimumab found an increased rate of severe infection (11% vs. 0.5%) compared to patients treated with other IBD medications.3 A retrospective case-control study from the Mayo Clinic showed no increase in opportunistic infection with combination anti-TNF and thiopurine therapy.31 A community-based retrospective cohort study of patients on anti-TNF therapy found that 44% of older patients versus 32% of younger patients developed infection, but this was not statistically significant.36 Another study examining claims data of >20,000 matched Crohn’s disease patients found rate ratios of 6.18 and 1.75 for opportunistic infection and sepsis in patients on combination anti-TNF and thiopurine therapy, but this was not statistically significant. Other studies have suggested an increased risk of adverse events or an increased rate of anti-TNF discontinuation in patients > 60 years old.38,39 After 24 months, 47% of older anti-TNF users stopped therapy compared to 10% of younger patients.39 Among the 38 older IBD patients who ceased therapy, 8 (21%) stopped therapy due to infectious complications. Six of the eight were either on concomitant thiopurines or corticosteroids.39 Although dose or duration with monotherapy infliximab does not appear to increase the risk of serious infection, it’s unclear if this holds true for combination infliximab and thiopurine therapy.12

Narcotic and corticosteroid therapy have consistently been associated with serious infections in IBD. Narcotics are associated with almost a two-fold increase in infections.12 Meanwhile, corticosteroids appear to drive the infection risk among patients undergoing medical therapy, especially in two- or three-drug regimens that include thiopurines.12,31 A population-based cohort Canadian study revealed a time-dependent risk of infection among corticosteroid users in incident older IBD patients.40 Despite these findings and guidelines that strongly state against the use of corticosteroids for maintenance therapy in CD and UC,21,41 one study showed that 32% of older IBD patients were on chronic corticosteroids while just 10% were treated with thiopurines or biologics.20

Hospitalizations and Surgery

Rates of hospitalization for UC and CD are rising and this has been associated with significantly increased costs.9 Infections account for over a quarter of all IBD hospitalizations and infection-related inpatient stays are associated with excess hospital stay, higher costs, and a four-fold increased mortality.13 Elderly patients account for an inordinately high percentage of IBD-related hospitalzations.1,42 These hospitalizations are associated with increased costs and mortality rates in older IBD patients even when adjusting for comorbidity.42

Among elderly, nosocomial infections cause a particularly high disease burden. Older patients have longer length of stays and are more likely to be discharged to skilled nursing facilities.7 The inpatient elderly patient is at higher risk for C. difficile- associated diarrhea, nosocomial pneumonia, foley- associated urinary tract infections, and intravenous catheter-associated infections. These infections have been associated with worse patient outcomes in IBD patients.16,43

Although most hospitalized and outpatient IBD patients can be treated effectively with medical therapy, surgical intervention is often required. Using the Nationwide Inpatient Sample, older patients were less likely to undergo nonelective surgery for UC but as likely to undergo CD-related surgery as their younger counterparts.42 The overall risk of complications between elderly and nonelderly patients was similar.42 A recent population-based cohort study found that elderly IBD patients prescribed corticosteroids were significantly more likely to have undergone surgery.40 Few studies report on the non-medication related risk of infectious complications after IBD-related surgery. A single center study found that after controlling for duration of disease, previous surgery, medications, and comorbidity, patients ≥60 years old had a higher post- operation wound infection rate than younger patients (13% vs. 1%).44

Most studies evaluating the risk of infection following IBD-related surgery have examined the effect of preoperative anti-TNF therapy on postoperative complications. A meta-analysis reported a significantly higher rate of infectious postoperative complications in anti-TNF treated CD patients (OR 1.45, 95% CI: 1.03- 2.05) but not in UC.45 The data regarding the preoperative use of corticosteroids and immunosuppressants and the associated postoperative complications is mixed, especially in the elderly.46 Part of the controversy with preoperative biologic and thiopurine therapy is that disease activity, itself a risk for postoperative infection, often is not accounted for in the studies examining postoperative infections.

Strategies Going Forward

Health care costs for chronic medical conditions like IBD are significant and are expected to grow with an aging population. Recognizing the factors behind these costs and minimizing their impact is key. Among elderly patients, the clinical and financial burden associated with adverse events like infection is substantial. Because clinical symptoms in IBD often do not correlate with active inflammation, an important strategy to balance the risk of therapy and potential infectious complications is objective assessment of disease activity through labs, imaging, and colonoscopy. Ongoing objective evaluation can help ensure that patients are adequately treated and decreases the risk of hospitalization and surgery. Due to the mild disease course of IBD and concern for adverse events associated with immunosuppressives in the elderly, a “step-up” treatment approach, utilizing nonimmunosuppressives before advancing therapy, often is used to treat underlying inflammation. Advanced age is not a contraindication for use of thiopurines and biologics, and in moderate to severe disease, these medications may be indicated. In general, monotherapy with either biologics or thiopurines, rather than the combination of the two, is typically preferred in older IBD patients.

Beyond assessing patients for appropriate therapy, other strategies to prevent infection among elderly IBD patients exist. In hospitalized patients, these include appropriate antibiotic use to avoid C. difficile and limiting urine foley catheters and the duration of mechanical ventilation to prevent hospital-acquired pneumonia.47 Among IBD patients specifically, limiting corticosteroid use for induction of remission in IBD, updating vaccinations for influenza and pneumococcal pneumonia, and the use of sterile techniques for central venous catheters placement are not only imperative for effective patient care but are part of the Physicians Quality Reporting System (PQRS) by the Centers for Medicare and Medicaid Services (CMS).48

Malnutrition and polypharmacy are potentially modifiable risk factors for infection in elderly IBD. Assessing nutritional status is an important aspect of care in IBD. Nutritional care involves identifying deficiencies and providing appropriate supplementation. Polypharmacy can provide challenges in IBD management and in the elderly, medication reconciliation can often identify unnecessary prescriptions.49 Part of an effective approach to malnutrition and polypharmacy involves a multi-disciplinary collaboration between dieticians, pharmacists, primary care physicians, and gastroenterologists.

There is a paucity of data in elderly IBD and the risk of infection in the age group. Further research is needed examining the natural history of IBD, the efficacy and complications of various medical and surgical therapies, appropriate clinical goals of therapy, and the most common infections among elderly patients. Until then, guidelines and recommendations that direct the care of all adult IBD patients can be utilized in the elderly to prevent serious infections. The American College of Gastroenterology suggest testing for tuberculosis, hepatitis type B, and in endemic areas, specific fungal infections, prior to initiation of biologics.21,41 Additionally, the CDC recommends patients over the age of 65 undergo vaccinations for influenza, pneumococcal pneumonia, and zoster. In the setting of immunosenescence and multiple comorbidities, older adults may benefit from post-vaccination titers to determine if further booster shots are needed.

Download Tables, Images & References

GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, #6

Median Arcuate Ligament Syndrome

Read Article

In this article, we discuss the pathophysiology, diagnosis and treatment of median arcuate ligament syndrome (MALS), an uncommon disorder characterized by epigastric abdominal pain accentuated by meals and weight loss associated with nausea,vomiting and gastroparesis.

Median arcuate ligament syndrome is an uncommon disorder first described in the 1960s. It is characterized by epigastric abdominal pain accentuated by meals and weight loss associated with nausea, vomiting and gastroparesis. Abnormal gastric electrical rhythm has also been reported. Abdominal bruit is a striking feature that is present in some cases. It is a diagnosis of exclusion that should be considered when there is a subjective presentation of severe epigastric and right upper quadrant abdominal pain which is out of proportion to objective findings. Whether using Doppler study, CT angiography, MRA or angiography, the main and most important goal is assessing both inspiratory and expiratory phases of the celiac artery to demonstrate reduction in the compression during inspiration. The treatment is surgical release of the median arcuate ligament to achieve decompression of the celiac artery and the celiac plexus. An evolving role for endoscopic ultrasound both in diagnosis and management is also discussed.

Ihsan Al-Bayati, MD, First Year Resident, Department of Internal Medicine, Texas Tech University, Paul L. Foster School of Medicine Richard W. McCallum, MD, Professor and Founding Chair of Medicine, Department of Internal Medicine Director, Center of Neurogastroenterology and GI Motility, El Paso, TX

INTRODUCTION

Median arcuate ligament syndrome (MALS), also known as celiac artery compression syndrome (CACS), Dunbar syndrome and celiac axis syndrome is a cause of chronic epigastric and right upper quadrant abdominal pain that is explained by the median arcuate ligament, a fibrous tissue connecting the two crura of the diaphragm, compressing the celiac artery and its companion structure, the celiac ganglion.1 Theories explaining the pathophysiology of the disease suggest either neurogenic or vascular origin.2 The clinical presentation is with abdominal pain, weight loss and gastroparesis. It is a diagnosis of exclusion. Most patients will undergo extensive laboratory and imaging workup looking for the diagnosis and some might undergo unnecessary surgical procedures like cholecystectomies and appendectomies.3 The treatment traditionally has been surgical with the goal of releasing the median arcuate ligament (MAL), resulting in restoration of blood flow to the celiac artery and relieving the entrapment of the celiac ganglion fibers.4,5

Etiology and Pathophysiology

MALS or CACS, also named Dunbar syndrome is a chronic epigastric and right upper quadrant abdominal pain exacerbated by eating and explained by the compression of the celiac artery by the median arcuate ligament at the level of the diaphragm.4

Understanding the anatomy of the MAL and the extensive collateral blood supply formed by the celiac artery, superior mesenteric artery (SMA) and the inferior mesenteric artery (IMA) is a key to understanding the pathophysiology of MALS.

The MAL is a fibrous structure that connects the diaphragmatic crura and crosses the aorta just proximal to the origin of the celiac artery. The celiac plexus originates from somatic branches of the phrenic and vagus nerves, parasympathetic preganglionic and sympathetic postganglionic fibers, and preganglionic splanchnic nerves. Its anatomic relationship to the celiac artery origin means that the MAL would compress both the celiac artery as well as the celiac ganglion.6 (Figure 1).

It was first suggested that the compromise of blood supply by compression of the celiac artery would lead to post prandial ischemia and hence worse abdominal pain. However the SMA and IMA are widely patent in this entity and the stomach has extensive collateral blood flow from the gastric and epiploic arcades leading to the conclusion that ischemia is not the explanation for the abdominal pain and other associated symptoms. It was suggested later that pressure on the celiac plexus might be the main etiological factor in MALS2 and thus it could also explain the accompanying findings often present in addition to the abdominal pain, namely nausea, vomiting, gastroparesis, and gastric electrical dysrhythmias.

Many theories have been proposed to explain this altered anatomy including congenital origin as it has been found in children and twins,7,8 as well as traumatic origin.9 The presentation in adults could be explained by a combination of a congenitally early take off origin of the celiac artery and/or an abnormally thickened MAL with or without accompanying arteriosclerosis in the vessel that may predispose to the “narrowing” finding on expiration.

Clinical Manifestation

Most patients report chronic epigastric and right upper quadrant abdominal pain which is accentuated after meals. Weight loss is explained by reluctance to eat for the fear of provoking pain. There are also symptoms that are manifestations of delayed gastric emptying, namely nausea and vomiting. In addition the normal gastric electrical rhythm has been reported as irregular (e.g. tachygastria) contributing to nausea and vomiting as well as impaired gastric motility. This is all consistent with the neurogenic pathophysiology of the syndrome by inhibiting the gastric neuromuscular function.2 As previously stated, these patients usually undergo extensive workups including computed tomography (CT) scans, magnetic resonance imaging (MRI), angiographies, and some even undergo surgical procedures including cholecystectomies, appendectomies, laparoscopic or even gynecological procedures to make the diagnosis or at least try to relieve the symptoms[10].

On physical examination one striking feature is the finding of an abdominal bruit present in up to thirty five percent of patients based on a review of cases from 1963 to 2012.6 In addition there is epigastric and/or right upper quadrant tenderness. Other non-specific findings might be weight loss and cachexia.

Making the Diagnosis

As previously explained, MALS is a diagnosis of exclusion to be considered when the subjective presentation of upper abdominal pain is dominant in the absence of any objective findings. Other causes of upper abdominal pain including but not limited to gastroesophageal reflux disease, pancreatitis, cholecystitis, gastric outlet obstruction and chronic intestinal ischemia from vasculitis or arteriosclerosis have to be considered. Extensive testing and therapy directed at these suspected causes have been unsuccessful.

This syndrome is seen more in females ranging in age between 40-60 years. The fact that the abdominal pain is exacerbated by eating and the possible presence of a bruit along with significant weight loss raises the index of suspicion for the diagnosis.4 Imaging is required to confirm the celiac artery compression by the MAL and other imaging is necessary to exclude any other causes of the patients’ symptoms.

The diagnosis can be made through different imaging modalities including duplex ultrasound, CT angiography, magnetic resonance angiography, and arteriography. The findings that are specific for the diagnosis include compression of the celiac artery with changes in the degree of obstruction related to inspiration and expiration, post compression dilation, and elevated velocities of blood flow.6,11 This is caused by two physiological phenomena; the first is that the aorta is displaced both anteriorly and inferiorly during inspiration. Second, as the diaphragm moves down during inspiration, the crura will relax and the compression on the celiac artery will be relieved.

Duplex Ultrasound

Performed during deep expiration, duplex ultrasound shows increase in the blood flow velocity across the compressed area of the celiac artery and supports the presence of constriction caused by the MAL.12 An example of the change in velocities is illustrated in two cases reported by Alper Ozel et al.13 In the first patient, the peak systolic blood flow velocity during deep inspiration and expiration were 135 cm/second and 308 cm/second, respectively. In the second patient, the peak systolic blood flow velocity during inspiration and expiration were 276 and 430 cm/second, respectively. The advantages of duplex ultrasound over CT angiography or arteriography are that it is noninvasive, less expensive and does not expose the patient to radiation or contrast.

CT Angiography (CTA) and Magnetic Resonance Angiography (MRA)

CTA has several advantages in making the diagnosis over arteriography.1 It shows the diaphragm and its relation to the celiac and SMA. One can rotate the three dimensional images in real time into different viewing angles to find the optimal one. All these options can be achieved with a single dose of contrast and a single dose of radiation compared to arteriography where each view requires additional contrast and radiation exposure, besides the fact that it is less invasive and less expensive than arteriography.

MRA has further advantage of no radiation exposure.11 Both CTA and MRA can be used to document post-operative relief of compression.14

Arteriography

The gold standard for diagnosis of MALS is the lateral view of aortic angiography.5 It shows asymmetric focal narrowing in the origin of the celiac artery of more than 50% during expiration with or without distal dilation. Again, the narrowing changes with the respiratory cycle, being improved during inspiration (Figures 2 and 3). Collaterals may be seen in the anteroposterior view as well as retrograde filling of the celiac via the dilated gastroduodenal artery.

Venkat Kalapatapu et al proposed a new technique to confirm the diagnosis of MALS.15 The idea was to steal the blood supply from collaterals by injecting a vasodilator after selective cannulation of the SMA; a positive test leads to reproduction of symptoms. Four out of eight patients who had celiac artery compression and patent SMA had positive test and underwent successful surgical treatment. Three out of four were asymptomatic at follow up and one patient had mild abdominal discomfort.

Treatment

When the diagnosis is confirmed with imaging in patients with persistent and unexplained upper abdominal pain by evidence of celiac artery compression, there is no medical therapy. Surgery is the traditional option for those patients. There are different modalities of surgery. The traditional approach is decompression of the celiac artery and celiac plexus by the division of the fibers of the MAL.2,16 Another approach does achieve decompression with angioplasty and vascular reconstruction but does not address the role of the celiac plexus.17,18 Laparoscopy and robotic-assisted laparoscopic approach have been utilized successfully.6,14,19,20 Intraoperative pre- and post- decompression flow velocity studies are performed routinely to increase the success of the procedure. Post-operative angiography usually still shows some mild compression of the celiac artery (<30%) during expiration.

Evolving and New Concepts

Endoscopic ultrasound (EUS) can be a good predictor of response to surgical decompression and a good way to strengthen the diagnosis of MALS. The technique is EUS guided injection of the celiac ganglion with xylocaine and monitoring over the next weeks whether there is any symptom improvement (Figure 4). If so, then there would be more confidence in the diagnosis and hence the decision for surgery.

Another role for EUS is EUS-guided injection of xylocaine and alcohol into the celiac ganglion to further enhance the results of post-surgical decompression when there is some remaining abdominal pain component. EUS guided therapy could also replace the need for repeated surgery should there be recurrence of the symptoms during long term follow up.18

Outcome and Prognosis

Following surgical decompression, the outcomes have varied widely in the literature mainly because the patients differed in presentations and comorbidities. While symptoms have resolved in most patients after intervention, some others did not have appreciable clinical benefit.3,21

Post-operative pain relief was achieved in most patients treated with open or laparoscopic median arcuate ligament decompression.6 Reilly et al. reported in their study the outcome of 51 patients followed after surgical treatment for a mean of 9 years.21 They concluded that the factors that were associated with the best success rate were post prandial pain (81 percent of patients were cured), age between forty and sixty (77 percent of patients were cured) and pre-surgical weight loss of 20 pounds or more (67 percent of patients were cured). On the other hand patients with an atypical pain pattern, age more than 60, psychiatric disorders or alcohol abuse and weight loss of less than 20 pounds showed less success rate after intervention. In addition if patients had required chronic narcotic use to address pain prior to surgery their response was also less optimal.

SUMMARY AND HIGHLIGHTS

  • MALS is an uncommon cause of chronic epigastric and right upper quadrant abdominal pain that is out of proportion to any objective data gathered by diagnostic testing.
  • Pain is not controlled medically and patients may be requiring narcotics.
  • Additional accompanying findings are nausea, vomiting, unexplained gastroparesis and weight loss.
  • Whether using Doppler ultrasound, CT angiography, MRA, or angiography, obtaining both inspiratory and expiratory phases is crucial to make the diagnosis since relief of compression on the celiac artery during inspiration must be demonstrated.
  • Surgical decompression relieves abdominal pain, nausea, vomiting, gastric dysrhythmia, and gastroparesis in most patients but a subset have some continuing pain component.
  • There are new roles for EUS in the management of MALS.

A) Pre-operatively, it could be a good predictor for surgical response by monitoring patients’ symptom relief after EUS-guided celiac ganglion injection.

B) It has a therapeutic role of celiac plexus neurolysis to supplement the surgical outcome. Furthermore, it could be an alternative to future repeat surgery.

Download Tables, Images & References

A CASE REPORT

Henoch Schonlein Purpura: A Known But Often Forgotten Culprit in Gastrointestinal Bleeds

Read Article

1Minesh Mehta, MD, 2Richard P. Rood, MD, FACP, FACG, AGAF, FASGE, 1Department of Internal Medicine, 2Digestive Disease Division, University of Cincinnati Medical Center, Cincinnati, OH

INTRODUCTION

We describe an adult case of Henoch Schonlein Purpura presenting with abdominal pain and gastrointestinal bleeding. Colonoscopy revealed multiple erythematous, hemorrhagic, and ulcerated lesions throughout the colon. Biopsies of skin lesions were consistent with leukocytoclastic vasculitis and positive for IgA immunoflourescence.

Case Report

A 45-year-old Caucasian female with primary biliary cirrhosis presented with a 4-day history of nausea, vomiting, diarrhea and abdominal pain.

The abdominal pain started in the right lower quadrant but progressed into a more diffuse, generalized abdominal pain. She quickly developed mucoid, non-bloody diarrhea. Her appetite diminished and she subsequently developed nausea and vomiting. Within 24-48 hours after the onset of gastrointestinal (GI) symptoms, she developed a rash on both lower extremities that began on the feet and spread to the upper legs, groin and arms. The rash was painful and burning in nature but not pruritic. The patient denied recent medication changes, sick contacts, recent insect bites or any history of a similar rash. On review of systems she noted diffuse myalgias and arthalgias but denies fevers, chills and night sweats.

Her medications included albuterol, aspirin, ferrous gluconate, prozac, furosemide, omeprazole, oxycodone, potassium supplement, simvastatin, topiramate and ursodiol. Her past medical and surgical history included diabetes mellitus, depression, hyperlipidemia, primary biliary cirrhosis, lymphedema, meningioma with resection, an incisional hernia repair, debridement of abdominal wound, a laparoscopic cholecsytectomy and a total abdominal hysterectomy during which a small bowel resection was done.

On admission her vitals were normal. Her exam was significant for multiple discrete coalescing 2-10mm erythematous and violaceous palpable, non-blanching, petechiae and purpura involving feet, legs, groins and arms. Her lower extremities also showed signs of chronic venous stasis with 2+ pitting edema. Her abdominal exam exhibited positive bowel sounds, mild tenderness to palpation and distension but there were no peritoneal signs.

Laboratory analysis showed anemia with hemoglobin of 11.5 g/dL and mild hypokalemia.3,4 Alkaline phosphatase was elevated to 169 (baseline for her) however the rest of her liver panel was negative. Urinalysis revealed 12 RBCs and 30 mg/dL protein. Computed tomography (CT) scan of the abdomen revealed diffuse wall thickening of the colon and distal ileum with inflammatory stranding without evidence of bowel obstruction.

An infectious workup for the diarrhea was pursued including stool cultures, ova and parasites, Clostridium difficile toxin and stool white blood cells. Additionally, an autoimmune panel was sent since vasculitis was on the differential. Inflammatory bowel disease was considered, and the patient was scheduled for a colonoscopy. Dermatology was consulted for skin biopsy. The infectious workup was negative. The complete autoimmune panel was negative except for anti-mitochondrial antibodies. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were elevated to 90 and 8.5 respectively. She developed dark, bloody, sticky stools on her second day of admission with a concomitant drop in hemoglobin. She was scheduled for colonoscopy and started on IV solumedrol 60mg daily.

Biopsy of the skin lesions revealed a positive IgA immuno-fluorescence. Colonoscopy gross findings showed focally, edematous, erythematous, hemorrhagic, thickened and ulcerated lesions of the sigmoid, descending and transverse colon highly suggestive of vasculitis. Colonic pathologic findings showed chronic inflammatory infiltrate with a peri-vascular orientation. A few small vessels showed lymphocytes within their walls.

DISCUSSION

The combination of clinical presentation and positive IgA immuno-fluorescence on dermatopathology supports our diagnosis of HSP. HSP is a leukocytoclastic vasculitis involving IgA immune complex deposition in small vessels. It is classically a clinical diagnosis characterized by palpable purpura, abdominal pain, arthritis/arthalgias and hematuria. Biopsy of the skin and kidney play a confirmatory and prognostic role. In general, prognosis is good, except for patients with renal involvement.1 HSP has a peak incidence in the first and second decades of life with the annual incidence in children estimated at 14 per 100,000.3 The incidence of HSP in adults is significantly less at 1.3 per 100,000, with a mean age of presentation at 50 years old. Adults suffer higher rates of severe and atypical gastrointestinal complications.3 Mucosal gastrointestinal involvement typically affects the small bowel, however our patient had significant colonic involvement. Steroid therapy improves GI symptoms by decreasing intestinal wall edema and might prevent complications like intussusceptions.4

CONCLUSION

We report a 45-year-old female with a history of primary biliary cirrhosis presenting with a GI bleed caused by HSP. In this patient, abdominal pain and bloody diarrhea were the initial symptoms followed by purpuric rash. While gastrointestinal involvement is common in HSP, the diagnosis is difficult when gastrointestinal symptoms precede cutaneous manifestations. Primary care physicians should consider HSP in a PBC patient that presents with abdominal pain. Identifying HSP early as the cause of GI bleed is important because management of HSP includes steroids. Initiating proper therapy early in the disease course can prevent complications like perforation, intussusception, massive GI bleed and bowel infarction requiring surgical intervention.

Download Tables, Images & References

FRONTIERS IN ENDOSCOPY, SERIES # 15

Bile Duct Injuries: Multidisciplinary Evaluation and Treatment

Read Article

Here we discuss bile duct injuries, which can have substantial medical and psychological impact on patients and can require significant healthcare resources for diagnosis and management. They are most commonly treated using endoscopic techniques, but may require a multi-disciplinary approach with percutaneous and surgical approaches as well. The topic of bile duct injuries pertains to several medical specialties including general and transplant surgery, gastroenterology, interventional radiology, and general medicine services which may work as a multidisciplinary team to formulate an individualized plan for each patient.

Tyler R. McVay MD, University of Utah School of Medicine, Gastroenterology and Hepatology. Douglas G. Adler MD, FACG, AGAF, FASGE, Associate Professor of Medicine, Director of Therapeutic Endoscopy, Director, GI Fellowship Program, Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, Salt Lake City, UT

INTRODUCTION

Bile duct injuries can have substantial medical and psychological impact on patients and can require significant healthcare resources for diagnosis and management. Iatrogenic injury during surgery is the most common etiology, but both blunt and penetrating trauma can cause bile duct injuries as well. There is a significant prevalence of variant biliary anatomy that poses a risk for biliary injury during surgery. Bile duct injuries are most commonly treating using endoscopic techniques but may require a multi- disciplinary approach with percutaneous and surgical approaches as well. The topic of bile duct injuries pertains to several medical specialties including general and transplant surgery, gastroenterology, interventional radiology, and general medicine services which may work as a multidisciplinary team to formulate an individualized plan for each patient.

CAUSES OF BILE DUCT INJURIES

Laparoscopic Cholecystectomy

Bile duct injuries most commonly occur during surgery, and the surgery most frequently implicated is laparoscopic cholecystectomy. Bile ducts can be accidentally clipped, lacerated, avulsed, or completely transected during surgery, with the most severe injuries being the least common. Cystic duct remnant injuries have been and remain the most common injury following cholecystectomy. (Figure 1) The laparoscopic approach to cholecystectomy was introduced in the late 1980s, and although it provides many advantages over open cholecystectomy, it has been associated with a higher rate of biliary complications.1,2,3,4,5,6 The rate of bile duct injury for open cholecystectomy has been reported to be 0.1-0.2% (although it has been reported to be as high as 0.75%).2,3 Many large population-based studies have estimated that the rate of bile duct injury for laparoscopic cholecystectomy is 0.3-0.5%.1,2,4,5,6

Due to intra-operative difficulties, surgeons convert about 4.7-8.2% of laparoscopic cholecystectomies to open procedures. The principal reason for converting in these cases is poor or limited visualization, distorted anatomy due to inflammation, and to control bleeding.4 Patients with a history of upper abdominal surgery often have distorted anatomy as well and are more likely to require conversion to open cholecystectomy.5 There is a learning curve associated with the technical skill required to perform laparoscopic cholecystectomies. One study found that novice surgeons who have performed less than ten laparoscopic cholecystectomies endure a bile duct injury rate of 0.49%, but surgeons with a tally greater than a hundred have a rate of only 0.04%.5

A newer laparoscopic approach, known as single- port laparoscopic cholecystectomy, is typically performed through a single incision site in the umbilicus and poses additional opportunities and challenges for surgeons. This new approach is less invasive and potentially results in quicker recovery time, less post- operative pain, and better cosmetic results for patients.7,8 A recent meta-analysis of eleven randomized controlled trials revealed a nonsignificant difference in the bile duct injury rate comparing the single-port technique (0.4%) with conventional laparoscopic cholecystectomy (0%) with use of three or four ports.8 However, the authors recognized that only two of the included trials in the meta-analysis offered evaluation of bile duct injuries, which limits the validity of the results.8

ORTHOTOPIC LIVER TRANSPLANT

Anastomotic Injuries

Liver transplant patients, both recipients and living donors, are at risk for bile duct injuries. Despite advances in surgical technique, biliary complications are still reported in 10-39% of liver transplant recipients, including strictures, leaks, anastomotic dehiscence, or a combination thereof. 9,10,11,12 Strictures can occur at the site of the bile duct anastomosis or at distant locations in the biliary tree, and bile leaks can result from a failed anastomosis or direct injury to bile ducts. The anastomosis of the bile ducts between the donor liver and recipient can occur via a duct-to- duct, end-to-end choledochocholedochostomy, or via hepaticojejunostomy, and strictures occur with any of these approaches.9,11,12 Anastomotic strictures can result from surgical technique or bile duct ischemia that results in fibrosis and stenosis of the anastomosis.9 (Figure 2) The risk of developing an anastomotic stricture increases with time from transplant surgery, with a rate of 6.6% at 1 year and 12.3% at 10 years.9

The following risk factors have been associated with the development of anastomotic strictures after orthotopic liver transplant: the presence of a post- operative bile leak, female donor-male recipient transplant combination, and a more recently performed transplant (although this may reflect improved diagnosis and increased graft survival which allows more time for anastomotic strictures to develop).9,11 A direct duct- to-duct anastomosis has been associated with a higher risk of post-transplant biliary complication than Roux- en-Y hepaticojejunostomy.12 Anastomotic strictures have a high recurrence rate of nearly 20% after initial successful treatment. Patients at risk for recurrent anastomotic strictures are those who experience a bile leak or have a longer time to presentation.13

Non-anastomotic Injuries

Non-anastomotic biliary strictures following orthotopic liver transplant can occur for several reasons. Bile duct ischemia from hepatic artery thrombosis is a recognized cause of non-anastomotic strictures.9 Ischemic-type biliary lesions, characterized by diffuse intrahepatic biliary strictures and dilatations in the absence of hepatic artery thrombosis, occur in 5-15% of orthotopic liver transplant patients and are not completely understood.14 Proposed risks for ischemic-type biliary lesions include compromised blood flow to the peri-biliary capillaries, immunologic injuries, and cytotoxic injuries from bile salts.14,15 Efforts to provide better perfusion of the small peri-biliary capillaries at the time of graft retrieval have resulted in a decreased incidence of ischemic-type biliary lesions.15 Other known causes of non-anastomotic strictures include ABO blood type incompatibility and immunologic rejection.9

Adult Living Donor Liver Transplant (ALDLT)

Approximately 1/3 of adult living donor liver transplantation recipients will develop some sort of biliary injury, although this rate has been reported in some centers to be as high as 67%.10,11 The incidences of bile duct leaks and strictures are similar in ALDLT recipients. For right hepatic lobe recipients, the anastomosis of the donor right hepatic duct to recipient common hepatic duct is associated with the lowest incidence of biliary complication when compared to all other anastomosis types.11 When donor liver grafts have more than one bile duct, a Roux-en-Y hepaticojejunostomy anastomosis is often used. Three- duct donor grafts have been associated with increased biliary complications when compared to single-duct donor grafts. The difference likely reflects a higher risk of bile duct ischemia when several small ducts are involved rather than a single large duct.11

The donors of ALDLT can also experience bile duct injuries. Bile leaks occur in 4-6% of living liver donors and are more common than bile strictures.16,17 Right lobe donors endure a higher bile leak rate and overall complication rate than left-sided donors.16,18,19 Right lobe grafts provide more liver parenchyma that can accommodate increased portal vein flow to the recipient, however this comes at the cost of a larger resection margin with increased risk of bile leak in the donor.16,20 A prospective study showed bile leaks in 7% of right hepatectomies and in 4% in left lateral hepatectomies and left lobe hepatectomies. Repeat operations are required in 1-4.5% of all living donors to address the most severe complications, but most bile leaks are controlled with less invasive techniques such as endoscopic retrograde cholangiography with stent placement, percutaneous transhepatic drainage or ultrasound-guided drainage.16,17,20

Transcatheter Arterial Chemoembolization (TACE) and Chemoinfusion (TACI)

Transcatheter arterial chemoembolization (TACE) and chemoinfusion (TACI) are interventional radiology procedures used to treat solid hepatic malignancies. These procedures are most often used to treat hepatocellular carcinoma (HCC) but are also used for other hepatic tumors as well. TACE consists of infusing iodized oil mixed with a chemotherapeutic agent directly into the tumor, followed by the infusion of gelatin sponge particles to embolize the blood vessels surrounding the tumor.21 Subcapsular bilomas and focal bile duct strictures are potential complications of TACE, and they often present in the context of serious bacterial infections such as cholangitis.21 Leaks and, more commonly, strictures in these patients can present in an acute or delayed manner.

Bile duct injury from TACE can occur in hepatic lobes separate from the tumor location. The iodized oil with the chemotherapeutic agent is often injected via the common hepatic artery, which can lead to bile duct necrosis with biloma or stricture formation in any segment of the liver.21 The hypertrophied peri-biliary capillaries in a cirrhotic liver may act as a vascular shunt that protects against bile duct ischemia after TACE. In fact, Child-Pugh class A patients have a higher rate of bile duct injury (15.2%) following TACE when compared with Child-Pugh class B and C patients (2.7%).22 Bile duct injury from TACE is also more common with non-hepatocellular carcinoma tumors (38.9%) compared to HCC tumors (11.3%).22 TACI, which involves chemoinfusion without embolization, has a significantly lower risk of bile duct injury than TACE.21

Resection and Radiation of Hepatic Tumors

Patients may undergo partial hepatectomy as definitive treatment for hepatocellular carcinoma. Bile leaks are common post-operative complications and occur in up to 12.8% of cases.23 Pre-operative treatments such as TACE or radiofrequency ablation do not increase the risk for development of a post-hepatectomy bile leak per se. However, if these pre-operative treatments were complicated by a bile leak or stricture, then the patient is at increased risk for a post-hepatectomy bile leak as well. Prolonged operative time has also been identified as a risk factor for bile leak after hepatectomy.23

Patients with either primary or metastatic liver tumors may receive radiation therapy as an element of their cancer treatment. Delivery of radiation to these tumors creates a risk of developing fibrosis and bile duct strictures. Stereotactic body radiation therapy (SBRT), which involves accurate delivery of radiation directly to the tumor, is a potential therapy for tumors in high-risk areas such as the hepatic hilum that cannot otherwise be treated safely with surgery, TACE, or radiofrequency ablation. When specific radiation doses are used (40 Gy or less), SBRT has been associated with minimal biliary toxicity and is a viable option for treatment of tumors within the hepatic hilum.24

Traumatic Bile Ducts Injuries

Penetrating and blunt trauma can result in injuries to the structures of the portal triad, including the extrahepatic bile ducts, hepatic arteries, and portal vein. Traumatic injuries to these structures are infrequent but are associated with high mortality rates ranging 50-52% for vascular injuries but reported as high as 75% for portal vein injuries.25,26,27 Trauma resulting in extrahepatic bile duct injury carries a mortality rate of 10-31%, and high- grade traumatic injury to the liver has a mortality rate up to 37.5%.28,29 The majority of these mortalities occur on day of admission while in the operating room due to exsanguination from vascular injuries.25,28

The most common causes of penetrating trauma to bile ducts include gunshot wounds, stab wounds, and shrapnel injuries. Penetrating trauma often results in a partial bile duct laceration rather than a complete transection, although transection can be seen in some patients as well.25 Blunt trauma to biliary system is most often secondary to motor vehicle crashes but also includes falls and assaults. (Figure 3) Blunt force to the abdomen can also result in hematoma formation, which can cause extrinsic compression of bile ducts and lead to biliary obstuction.31

Trauma to the liver can result in bile duct injuries. Liver lacerations due to stab wounds or gun shot wounds can result in intrahepatic biliary complications in the form of a biloma or biliary fistula. A recent study of hepatic trauma identified that bile leaks occur more commonly in patients with penetrating trauma, those undergoing operative management, damage control surgery with packing of the liver and those with higher- grade liver injury.30 High-grade liver injuries (grade 3-4 on American Association for the Surgery of Trauma Organ Injury Scale) are associated with bile duct injuries in up to 25% of cases.28 Approximately 2.8-7.4% of patients who experience blunt hepatic traumas of all grades have a biliary complication, most commonly bile leaks with associated biloma formation.28,31

Variant Biliary Anatomy

The existence of aberrant biliary anatomy and anatomic variations of the biliary tree creates an increased risk for iatrogenic bile duct injury. Surgeons may or may not be aware of aberrant biliary anatomy at the time of surgery depending on the type of preoperative imaging obtained.

The duct of Luschka was first described in 1863 as a thin bile duct passing through the gallbladder fossa to join the right hepatic or common hepatic duct, although this can also manifest as a small duct that connects to peripheral right intrahepatic branches.32 The prevalence of the duct of Luschka has been reported in 4.6-30% of dissected liver specimens. The ducts are typically thin, measuring 1-2mm in diameter, with variable sites of origination within the liver and sites of union with the biliary tree.32,33

Magnetic resonance cholangiopancreatography (MRCP) of patients suspected of having pancreaticobiliary disease demonstrated anatomic variations in 24.2% of patients. These anatomic variations included an aberrant right hepatic duct in 4.8%, right posterior hepatic duct in 5.7%, trifurcation in 0.8%, low medial cystic duct insertion in 3.8%, long and short cystic ducts in 1.7% and 0.63% respectively, vascular compression of the common hepatic duct in 2.5%, and 2.3% of patients had more than one anatomic variation.34 Bile duct injuries originating from aberrant biliary anatomy have proven difficult cases for providers that necessitate multiple diagnostic modalities and, in some cases, a multidisciplinary approach, to diagnose and treat the underlying injury associated with the aberrant anatomy.35

DIAGNOSIS OF BILE DUCT INJURIES

Clinical Presentation of Bile Duct Injuries

The most common presenting symptom experienced by patients with bile leaks is abdominal pain, often accompanied by fever, due to the inflammation of the peritoneum caused by bile which may or may not become secondarily infected. Patients may also have abnormal liver function tests at presentation, although patients who have leaks alone often have normal serum bilirubin levels as the bile is pooling within the abdomen.2 An increase in serum bilirubin without elevation of transaminases may represent the presence of a bile duct injury, particularly a bilio-venous fistula where bile can flow down its pressure gradient and into the venous system.36

Biliary strictures often have a more insidious clinical onset with cholestatic symptoms such as jaundice and pruritus. The median time to presentation for patients with biliary strictures is 7 to 9.6 months but ranges as early as 6 days and as late as several years following the inciting surgery.2,37,45 Patients with biliary strictures can present acutely with cholangitis and serious bacterial infections as well.21 Patients may have concomitant biliary strictures and leaks depending on the severity of the injury. (Figure 4)

Diagnostic Imaging Modalities

The biliary tree can be imaged by multiple modalities, including MRCP, hepatobiliary scintigraphy (HIDA scan), and cholangiograms obtained by endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), and intraoperative cholangiogram (IOC). Several studies have investigated the efficacy of IOC during laparoscopic cholecystectomy, and overall they have concluded that obtaining an IOC in every cholecystectomy reduces the rate of bile duct injury from 0.42% to 0.21% and increases the rate of intra-operative detection of bile injuries from 21.7% to 76.9%.4,5,6,38,39,40,41 Opponents of universal IOC during cholecystectomy caution against the increased operative time, cost, and limited practical use of the procedure. One large study found that only 82.7% of attempted IOCs were successful, and the estimated additional operating to perform IOC was only 19 minutes.1,39

Bile duct injuries are most often diagnosed from a cholangiogram performed during ERCP or PTC, however many noninvasive imaging techniques, such as MRCP and HIDA scan, can be employed to evaluate the biliary tree as well. MRCP has been utilized to assess the biliary anatomy of donor livers prior to living donor liver transplantations and can detect variant biliary anatomy with a sensitivity of 85.6%.42

HIDA scan is a noninvasive nuclear medicine study used to evaluate the vascular flow and biliary drainage of the liver and extrahepatic bile ducts. The sensitivity of HIDA scan to diagnose bile leaks after laparoscopic cholecystectomy and liver transplantation has been reported to be between 83-100%.43,44 HIDA scan has proven to be successful at diagnosing traumatic bile leaks as well.31 Biliary strictures can also be detected by HIDA scan with a reported sensitivity of 75% and specificity of 97%, often manifesting as a failure of the radiotracer to reach the duodenum after protracted amounts of time.44

Treatment of Bile Duct Injuries

The treatment of bile duct injuries can often require a multidisciplinary approach with several therapeutic possibilities including surgery, endoscopy, and interventional radiology approaches. Bile duct injuries can be managed surgically by re-establishing biliary continuity through reconstructive surgery or by suturing open injuries, although in current practice most biliary injuries are primarily treated endoscopically if at all possible. If patient outcomes are the same, then non- surgical approaches are preferred.45

ERCP for Bile Duct Injuries

ERCP with dilation and stent placement and/or sphincterotomy (as needed) has proven to be a successful method of treating bile leaks and strictures and is the current gold standard and first line treatment for most biliary injuries.12,28,31,36,45-51 These therapies can open up strictures, and allow for stent placement to reduce the pressure gradient across a stricture or the sphincter of Oddi, which directs bile to flow downstream into the proximal duodenum and not out of the leak site. Directing the flow of bile away from the site of injury allows the defect to subsequently heal.

In patients with low-grade bile leaks (defined as bile leaks that are visualized during ERCP only when there is full opacification of the intrahepatic biliary tree with contrast, indicating that more pressure is required to force contrast and bile out of the duct injury site), endoscopic sphincterotomy alone has been reported to lead to successful resolution of the bile leak in 91% of patients, although many patients will receive a stent alone in this situation as stent placement is a lower risk maneuver than biliary sphincterotomy. Patients with high-grade bile leaks (visualized during ERCP before intrahepatic biliary tree opacification, indicating a more brisk flow of bile through the leak site) require either stenting or (rarely) surgical ligation for successful resolution of the leak.46 The reported success rate of treating post-surgical bile leaks with endoscopic placement of biliary stents ranges from 77-100%. 45,46,47,48,49

As one would imagine, less severe bile duct injuries have higher success rates with stenting than more severe or complex injuries. Of the Strasberg classification of bile duct injuries, Class A injuries (leak of cystic duct or small accessory duct) have reported success with ERCP and stent placement in 99% of cases. More severe Class E1 through E5 bile duct injuries (stricture or complete transection of the common bile duct or common hepatic duct) have a reported successful treatment in 77% of attempted ERCPs, but the majority require immediate surgical intervention.48

Bile duct strictures due to surgical injury often require long-term stenting with multiple follow-up ERCPs to obtain resolution of the strictures. Success rates of 71% and 74% have been reported after six and eleven months of stent therapy, respectively.45,47 Anastomotic strictures following OLT and ALDLT are successfully treated by endoscopic dilation and stenting in 74-88.9% of cases.9,12,49 However, up to 18% of patients have stricture recurrence after success initial treatment of the anastomotic stricture, and they may require anywhere from one to four additional ERCPs for successful treatment.13 The simultaneous presence of both a bile duct stricture and a bile leak following surgery is a well-documented risk factor for recurrent strictures.13,45

Endoscopists have long used plastic stents in the treatment of benign, post-operative biliary strictures. Uncovered metal stents, commonly used in the palliative treatment of malignant bile duct strictures, were trialed in 1990s for the treatment of benign post-surgical strictures as an alternative to plastic stents. Although they helped reduce the frequent stent exchanges required with plastic stents, metal stents encountered high rates of stent occlusion and stricture relapse due to ductal mucosal hypertrophy through the stent mesh with resulting recurrent obstruction which proved to be difficult to treat.50,51 Covered self- expandable metal stents (C-SEMS) that are removable have been developed to prevent stent occlusion and may be used for temporary stenting of benign bile duct strictures.52,53,54 Success rates of 88-90% have been reported for C-SEMS in the treatment of benign biliary strictures that were initially refractory to plastic stent treatment. Recurrence rates of 7.1-12% were reported within 16 months of stent removal.52,53 Post-liver transplant anastomotic strictures are often stented using an increasing number of plastic stents to progressively dilate the stricture, although this practice is much less common in the era of fully covered metal biliary stents. Fully covered metal stents, which can provide a similar dilation diameter as several plastic stents, have achieved similar resolution rates in anastomotic strictures.54 Metal stents do carry a risk of migration (ranging 16-24.2%) but most often migrate distally into the duodenum and are expelled without causing clinical complications.53,54 Furthermore, migration is not always to be considered a negative event as it may signify resolution of the underlying stricture.

Percutaneous Transhepatic Catheter (PTC) Drainage for Bile Duct Injuries

PTC is a non-surgical approach that is often attempted after failure of ERCP to treat bile duct injuries. PTC is also performed when bile ducts cannot be accessed by ERCP, often due to post-surgical bowel anatomy (most commonly in patients with a Roux-en-Y gastric bypass).50 PTC is performed by interventional radiologists and provides the same physiologic treatment as ERCP, via dilation and stent placement, but through a percutaneous transhepatic approach. 12,45,55,56 PTC with a bilio-enteric stent placed across the sphincter of Oddi has a reported success rate of 77.2-80% at treating bile leaks.45-50 This success rate is seen with nondilated intrahepatic bile ducts as well, which were once thought to be a contraindication to PTC due to difficult percutaneous accessibility.50 The success rate of treating post-surgical bile duct strictures with PTC dilation and stenting has been reported from 58.8-81%.12,55

Management of Traumatic Bile Duct Injuries

Patients with blunt and penetrating traumatic injuries to the biliary system can often be safely managed non- surgically via ERCP.28,31,36,57,58 Patients with bile leaks secondary to gunshot wounds and stab wounds have had successful resolution of bile leaks when managed non- surgically with sphincterotomy and/or stent placement.57

It is the standard of care to manage patients with blunt hepatic trauma non-surgically.36 One study evaluated non-operative management of severe, grade 4 and grade 5, blunt liver injuries (parenchymal disruption of 25-75% and >75% of a hepatic lobe, respectively) and found that ERCP successfully treated 81% of bile leaks in these cases. Two independent predictors for failed non-operative management were identified: admitting systolic blood pressure less than 100mmHg and presence of additional abdominal organ injury. Failure of non-operative management was seen in 23% of patients with both of these predictors and only 4% with neither.58 Complex bile duct injuries, such as complete transection or stricture of the common bile duct, common hepatic duct, or disruption at the level of hepatic duct bifurcation, almost always require surgical intervention after diagnosis by ERCP.41,48 (Figure 5)

Surgical Reconstruction as Treatment of Bile Duct Injuries

Referral to a tertiary medical center for surgical intervention is often necessary with severe bile duct injuries. Primary end-to-end anastomosis may be performed when the loss of tissue from the bile duct transection is not significant. This technique has been associated with a high rate of stricture formation at the anastomosis site, but nearly two-thirds of these strictures can be successfully managed endoscopically without further surgery.59 When end-to-end anastomosis is not possible, a Roux-en-Y hepaticojejunostomy (RYH) is the preferred treatment. Strictures can occur with RYH as well, but the stricture rate is reduced when the anastomosis is performed more proximally where right and left bile ducts join, rather than at a more distal site in the common hepatic duct.60 Patients with severe bile duct injuries may rarely develop chronic complications such as secondary sclerosing cholangitis with associated cirrhosis or acute liver failure; rarely, liver transplant can be required.61

Morbidity and Quality of Life after Bile Duct Injuries

Bile duct injuries and the subsequent therapies can result in short term and sometimes life long complications for patients.62,63 One study followed patients after surgical reconstruction for bile duct injuries, reporting a mean hospital stay of 17 days following surgery, with 38% requiring acute readmissions within the first year most commonly for cholangitis. At one year follow up, 62% of patients remained asymptomatic, 28% continued to have episodic cholangitis, and 10% had persistently elevated liver function tests but were asymptomatic.62 Another study evaluated patients at a mean of 70 months after treatment of bile duct injury following laparoscopic cholecystectomy, reporting 93% of endoscopic treatments and 84-94% of Roux- en-Y hepaticojejunostomies remained functionally successful without need for additional surgery. Despite the promising reports of these treatment success rates, the patients reported on questionnaires a significantly poorer quality of life on mental and physical scales compared to controls.63

CONCLUSION

Biliary injury can occur via many routes. Laparoscopic cholecystectomy and liver transplantations are the most common surgeries associated with bile duct injuries, but other treatments for hepatic malignancy such as TACE, partial hepatectomy, and radiation may result in bile duct injuries as well. ERCP remains the principal method of diagnosis and treatment using plastic or covered metal stents. Percutaneous and surgical approaches can be utilized as well to properly treat each individual case, and complex bile duct injuries often require multidisciplinary treatment.

Download Tables, Images & References

HEPATITIS C: A NEW ERA OF TREATMENT, SERIES #7

Knowledge Gaps About Hepatitis C Prognosis and Treatment Among Non-Gastroenterologists and Medical Students

Read Article

Given the availability of new Hepatitis C (HCV) therapeutics and increased potential for cure, it is necessary to assess knowledge about treatments among current and future physicians in the United States. Here, the authors aim to quantify the awareness of HCV curability and treatment among gastroenterologists, primary care physicians and medical students.

What is Current Knowledge?

  • New all oral regimens for chronic hepatitis C promise greater sustained viral response (SVR) rates.
  • Underreporting of hepatitis C (HCV) infection has been well documented in the literature.

What is New Here?

  • There is a lack of knowledge about HCV treatments and cure outside of hepatologists and specially trained gastroenterologists.
  • Primary care physicians (PCPs) and medical students are unaware of modern HCV treatments.
  • Experience managing HCV is associated with increased awareness of new therapeutics.

Introduction

In light of Centers for Disease Control and Prevention (CDC) and United States Preventative Task Force (USPTF) screening guidelines for HCV, we aimed to quantify the awareness of HCV curability and management among gastroenterologists, primary care physicians and medical students.

Methods

An online survey was disseminated to several email listservs affiliated with the Tulane University School of Medicine. Four categories of respondents were evaluated with Chi-Squared and Kruskal-Wallis testing: Gastroenterology (GI); Family and Internal Medicine (FIM); Clinical Medical Student (CMS); and Preclinical Medical Student (PMS).

Results

196 responses were analyzed (9 GI, 27 FIM, 90 PMS, and 70 CMS). Analysis identified differences in knowledge of HCV curability (p<0.001), experience managing HCV (p<0.001), and frequency of identifying interferon (p<0.001), ribavirin (p<0.001), or a protease inhibitor (p<0.001) as treatment modalities. GI respondents consistently demonstrated greater knowledge of HCV curability, management, and treatment. Less than 60% of FIM and only 12-30% of medical students were aware that HCV is curable.

Discussion

The FIM, CMS, and PMS groups lacked knowledge concerning HCV treatments and curability, which indicates a possible need for outreach to non-GI specialists and medical training sites.

INTRODUCTION

The hepatitis C virus (HCV) is estimated to infect 1.9-5.2 million Americans, with over 75% of cases becoming chronic.1,2 Many develop hepatic complications, such as cirrhosis or hepatocellular carcinoma, leading to total annual HCV management costs projected to exceed $9 billion by 2024.3,4

In the summer of 2012, the Centers for Disease Control and Prevention (CDC) advocated one time HCV screening for all persons born between 1945 and 1965, which the United States Preventative Task Force (USPSTF) later corroborated.5,6 This recommendation was likely related to the release of first generation direct antiviral agents (DAA), which have drastically increased sustained viral response (SVR) rates.7,8

Though underreporting of both acute and chronic HCV have been confirmed elsewhere,9-13 few studies have examined knowledge among healthcare providers (HCPs) in the United States concerning curability and current pharmacotherapy for HCV. The Institute of Medicine’s (IOM) 2010 report on viral hepatitis acknowledged a gap in provider knowledge about several aspects of HCV management, including the “sequelae of chronic viral hepatitis” as well as in “proper follow-up management for chronic infection”, but did not squarely assess understanding of curability.2 Studies assessing trainees’ knowledge are also scant and could only be identified from Eastern countries.14,15

Given the availability of new HCV therapeutics and increased potential for cure, it is necessary to assess knowledge about treatments among current and future physicians in the United States. We aimed to quantify the awareness of HCV curability and treatment among gastroenterologists, primary care physicians, and medical students.

METHODS

This is a cross-sectional study to assess the knowledge, attitudes and practices (KAP) of HCV pathogenesis and treatment among medical students and physicians at a single academic medical center (Tulane University School of Medicine in New Orleans, Louisiana).

Survey Creation

An online survey was created via GoogleForms, which included demographic (age, sex, zip code) and four study questions, listed in Table 1. Medical specialty or year of medical school education was also collected, as appropriate. To prevent bias by later study questions, Question 1 concerning HCV curability, was presented on a single page before the remaining questions. The word “Cure” was used in the place of “SVR,” as the authors did not believe the idiomatic hepatology language would be equally understood across all specialties. Students and faculty from the single center vetted the survey for clarity before distribution. Complete surveys are available in the online supplemental materials.

Survey Distribution

The KAP survey was initially distributed electronically to listservs of gastroenterology, family medicine, internal medicine and medical students on October 9, 2013. The subject line of the first recruitment email read “Louisiana Hepatitis Study”. Recruitment was considered complete if twenty-five responses were received or the survey was distributed to the listserv three times. When required, surveys were redistributed with the subject line reading: “Quick Survey for Louisiana Hepatitis Study”. A standardized form email was used to recruit survey responses (supplemental materials). Individuals 18 years of age or older who were either a current medical student or medical doctor affiliated with the single center were included.

Statistical Analysis

Data were downloaded from the GoogleSurvey tool, transformed for SPSS and divided into four subject populations for analysis: Gastroenterologist/ Hepatologist (GI), Family and Internal Medicine (FIM), Clinical Medical Student (CMS) and Preclinical Medical Student (PMS). For the study, PMS included first- and second-year, and CMS includes third- and fourth-year medical students.

Chi-squared or Fisher’s Exact were used to evaluate Questions 1, 2, and 4. Shapiro-Wilk testing for normality was performed on the Likert-scale responses of Question 3; none of the four subgroups were normally distributed (GI p=0.037; FIM p<0.001; CMS p<0.001; PMS p<0.001). Kruskal-Wallis testing was then employed for Question 3. SPSS Version 21.0 was used for analysis. Significance was set at a=0.05.

RESULTS

Survey Respondents

A total of 201 survey responses were collected (9 GI, 24 Family Medicine, 8 Internal Medicine, and 160 medical students). The initial survey completion rate among students exceeded expectations, but physician response rate was low and required multiple emails to the GI, Internal Medicine and Family Medicine listservs. Of the 8 Internal Medicine responses, 5 self-identified as specialists other than GI and were not included in the analysis. Family and internal medicine were combined to represent the primary care population. A total of 196 responses were evaluated (9 GI, 27 FIM, 70 CMS, and 90 PMS). The average age and sex distribution by subgroup are presented in Table 2.

Knowledge of HCV Curability (Question 1)

Chi-squared testing showed significant differences when comparing all four groups for knowledge of HCV curability (p<0.001): 100% of GI, 59.3% of FIM, 30.0% of CMS and 12.2% of PMS reported that HCV was curable. Proportional analysis showed that all four groups were significantly different from each other in awareness of curability.

Experience Managing HCV Infection (Question 2)

Chi-squared testing detected a significant difference in experience managing HCV patients (p<0.001). 100% of GI, 81.5% of FIM, 72.9% of CMS and 7.8% of PMS claimed experience managing HCV. Respondents with experience managing HCV had 4.883 the odds of reporting that HCV was curable (95% CI: 2.497 — 9.549; p<0.001).

Perception of Hepatitis C on Patient Health (Question 3)

Kruskal-Wallis testing found significant differences among subject populations on awareness of the extent of injury associated with chronic HCV (p=0.026). Mean and interquartile range was 4 (3-5) for GI, 3.67 (3-4) for FIM, 4.10 (4-5) for CMS and 3.80 (3-4) for PMS. No post-hoc comparisons were significant.

Knowledge of Hepatitis C Treatments (Question 4)

There was a significant difference in proportions reporting interferon as a drug used to treat hepatitis C (p<0.001): 100% of GI, 82.6% of FIM, 78.9% of CMS and 20.0% of PMS cited interferon. Proportional analysis showed that PMS had lower proportional knowledge of interferon than all other groups.

There was a significant difference in proportions reporting ribavirin as a drug used to treat hepatitis C (p<0.001): 87.5% of GI, 56.5% of FIM, 59.6% of CMS and 11.9% of PMS cited ribavarin. Proportional analysis showed that PMS had lower proportional knowledge of ribavirin than all other groups.

There was a significant difference in proportions naming a DAA (telaprevir, boceprevir, or sofosbuvir) as a treatment for HCV(p<0.001): 75.0% of GI, 17.4% of FIM, 14.0% of CMS and 5.0% of PMS cited one or more protease inhibitors. Proportional analysis showed that GI mentioned a protease inhibitor in greater proportions than all other groups.

DISCUSSION

This study exposed shortfalls of knowledge about the prognosis and treatments for hepatitis C. In light of the rapidly evolving field of HCV therapeutics and the recent joint release of guidelines by the American Association for the Study of Liver Disease and the Infectious Disease Society of America on screening and treatment of HCV, it is of great importance to assess healthcare provider knowledge.16

Greater knowledge of curability and treatment among GI was expected, as they are most involved in HCV management and research. With the recent release of second generation DAAs promising fewer side effects, lower rates of complication, and shorter treatment periods,17-19 it may fall on primary care physicians to discuss treatment with the HCV patient. Thus, with only 60% of FIM acknowledging curability for HCV in our cohort, and even fewer capable of mentioning a DAA, there is a clear need for improved outreach.

Similarly, underreporting of HCV is a serious issue increasingly documented in the literature.12,13,20 A recent NHANES report showed that only 32-38% of all HCV antibody positive people in the United States received follow-up care.12 Specialist referral of diagnosed HCV patients has failed to surpass 50% in several cross sectional studies.21,22 Definitive reasons for undertreatment and underreporting are not answered by the study, but it is reasonable to assume insufficient incentive for either with limited knowledge regarding its curability.

The low level of insight among medical students regarding HCV curability and pharmacological agents suggests that a push towards graduate medical education is necessary. Interestingly, CMS were able to mention interferon and ribavirin at higher rates than PMS, suggesting some exposure to early HCV treatments in clinical years.

There were several limitations to this study. Firstly, the data set was restricted to a single academic center, limiting generalizability and may be skewed by the university’s educational programming. Additionally, the initial protocol compared subspecialists with primary care and medical students, but the survey response rate among physicians was lacking and consequently subspecialists were excluded from analysis. Although respondents were instructed not to use outside resources, the online format for the survey created potential for bias by respondents researching answers.

CONCLUSION


We identified a gap in knowledge about HCV treatments and curability among primary care providers and medical students. Though a full policy discussion is beyond the scope of this paper, we recognize the need for a national assessment and possibly improved dissemination of information concerning HCV treatments to non-GI specialists and medical trainees. Without an appropriate fund of knowledge amongst medical trainees and general practitioners, patients with chronic HCV are wont to face difficulty in obtaining appropriate medical referrals for the most up-to-date treatments.

Download Tables, Images & References

GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #5

Cyclic Vomiting Syndrome: Diagnostic Criteria and Insights into Long Term Treatment Outcomes

Read Article

The alternating pattern of disease and disease-free periods distinguishes cyclic vomiting syndrome (CVS) from other disorders of nausea and vomiting. This entity has been increasingly recognized in adults and has resulted in significant morbidity and poor quality of life. Recent referral patterns suggest prevalence of up to 0.2% in the adult population and an explanation for nausea and vomiting in 12% of a referral population to a teaching academic center. In this article we discuss diagnostic criteria and insights into long term treatment outcomes.

Chad J. Cooper MD, MHA Richard W. McCallum, MD, Professor and Founding Chair, Department of Internal Medicine Division of Gastroenterology Texas Tech University Health Sciences Center, El Paso, TX

INTRODUCTION

Cyclic vomiting syndrome (CVS) in adults is a disorder characterized by recurrent abrupt bouts of nausea, vomiting and abdominal pain separated by variable periods of normal health. This alternating pattern of disease and disease-free periods distinguishes CVS from other disorders of nausea and vomiting. This entity has been increasingly recognized in adults and has resulted in significant morbidity and poor quality of life.1 Recent referral patterns suggest prevalence of up to 0.2% in the adult population and an explanation for nausea and vomiting in 12% of a referral population to a teaching academic center.2

Diagnostic Approach

CVS is really a diagnosis of eliciting a “classic” history of this disease. Patients typically present with a variable number of episodes of nausea, vomiting and mid-epigastric abdominal pain per year. During all presentations in adults there is accompanying severe mid-epigastric abdominal pain, with or soon after the onset of nausea and vomiting. This history of mid- epigastric abdominal pain tends to attract the need to exclude other sources since it can mimic an acute abdomen. Diagnostic Criteria of CVS is based on Rome III which includes the following list in (Table 1). These criteria were developed when CVS was predominantly only being recognized in children and abdominal pain was not a predictable concomitant feature.

The majority of CVS attacks occur without any warning although in retrospect patients report that up to 60-80% of CVS attacks can be associated with a trigger mechanism such as infection (chronic sinusitis and upper respiratory infections), psychological stress, emotional stress, physical stress (heavy exercise), lack of sleep, diet (chocolate, cheese), motion sickness and onset of menses.3-4 Many patients take hot showers or baths during the vomiting episodes and report a decrease in symptoms and therefore the contact with hot water is assumed to have a “relaxation effect”.

As far as contributing factors or etiologic “subgroups” approximately 24-70% of CVS patients report a personal or family history of migraines.1 However in adults the migraine subset is more in the range of 30-40% of the CVS population. Psychiatric disorders, such as anxiety, depression are frequent comorbid findings in CVS patients.6 The anxiety present in CVS patients, including panic disorder, has been reported to trigger attacks in 66% of cases.7 Anxiety can also be increased as a result of the burden of the illness, anticipation of the next vomiting episode or psychological trauma and experiences prior to the onset of CVS.3,7 Sometimes psychological disorders in CVS patients including depression are so dominant that co- management with a psychiatrist may be indicated.

Another identifiable subgroup is diabetes mellitus which is increased to 15% in the CVS populations compared to approximately 8% in normal population based studies. The theory proposed here is that elevated glucose levels, usually early in the course of diabetes, in the setting of genetically predisposed CNS chemoreceptors can trigger a vomiting cycle.

On review of the current literature of cyclic vomiting syndrome in adults marijuana use is present in 42-53% .8 The predictable scenario is a typical pattern of daily marijuana intake beginning in the teenage years for recreational use. The cyclic episodes of vomiting do not occur until at least 5 years of chronic daily use. A clinical entity termed cannabinoid hyperemesis syndrome has also been separately described and is actually the same clinical presentation as CVS.8 Cannabinoid hyperemesis syndrome is characterized by chronic marijuana use, cyclic episodes of nausea, vomiting, abdominal pain and frequent relief with taking a hot bath.9

Not all cannabis users develop cannabinoid hyperemesis syndrome. However the cumulative dose of marijuana, genetic factors, and psychological parameters may contribute to this condition. The pathophysiology of cannabinoid hyperemesis syndrome is unknown. There are some hypotheses proposed to explain this phenomenon: (a) accumulation of cannabis derivatives in the brain based on their lipid solubility and long-term half-life, (b) degradation of the cannabis ingredients to some potential emetic metabolites or toxins, (c) delayed gastric emptying induced by cannabis and (d) down-regulation or desensitization of the cannabinoid receptors due to chronic cannabis use.8,10 Another theory is that chronic cannabis is associated with inhaling toxins related to the various sources and preparation of the marijuana and over time these toxins could accumulate in the CNS.11 However, the major message is chronicity of >5 years with daily use leading to increasing storage in fat tissue in the brain and in those genetically susceptible individuals nausea receptors are activated. This setting is to be distinguished from the “legal use” of marijuana for cancer and pain related indications. In addition cannabis has been shown to acutely delay gastric emptying and this can also contribute to inducing a vomiting cycle.9,11

In our experience at an academic gastrointestinal motility referral center, we recently reviewed a total of 48 patients diagnosed with CVS, 37 females and 11 males with a mean age of 34.8 year old. The majority of the patients reported cyclic episodes occurring approximately every 2-3 months. Five (10%) patients had relief of symptoms with hot baths or showers and 11 (23%) had worsening of symptoms with stress, menses or sleep deprivation. Comorbidities included diabetes mellitus (31%), hypertension (23%), hyperlipidemia (15%), anxiety (48%), depression (25%), migraines (40%), family history of headaches/migraines (31%), panic disorder (11%), and chronic daily marijuana use (23%) for more than 5 years. Eleven (23%) patients were smokers, 7 (15%) had a history of alcohol use and 15 (33.3%) were given narcotics acutely at some time throughout the course of their disease during ED visits. Six (20%) of patients reported a significant disruption in their professional and/or personal social life. Fifteen (19%) patients had a cholecystectomy. Twenty-five (52%) had frequent ED visits before being diagnosed and treated.

Adult patients typically have been symptomatic for a long time before diagnosis. Patients often remain undiagnosed for some time due to lack of recognition of this clinical entity with reports suggesting a delay in diagnosis for as long as 8-21 years following onset of the symptoms.6,12 Over time without appropriate specific treatment, CVS cycles slowly begin to “coalesce” and become closer together and this can confuse the presentation and suggest more of a “chronic” entity such as gastroparesis. CVS results in a significant morbidity for patients with loss of time at work or school, a significant disruption in professional and personal life as well as an economic burden.9,12-13 CVS in adults can range from mild disease with infrequent episodes to severe debilitating disease requiring multiple emergency department (ED) visits and frequent hospitalizations.12 These patients often undergo multiple unnecessary diagnostic tests and procedures without any apparent clinical benefit. Abdominal pain and mild leukocytosis have prompted unnecessary cholecystectomies and other abdominal surgeries because CVS was mistaken for an acute abdomen.

Gastric Emptying Studies in CVS

Even though CVS has been increasingly recognized in the adult population, there is a lack of data as to the gastric emptying (GE) pattern. Using a standardized 4 hour egg beater scintigraphic method a normal GE is defined as < 90% retention at 1 h, < 60% at 2 h, and < 10% at 4 h. Rapid GE is defined as < 35% isotope retention at 1st hour and/or < 20% at 2nd hour.14 Delayed gastric retention is defined as a delay of greater than 90% at 1 h, 60% at 2 h, and 10% at 4 h based on normal data established for this standardized GES.14 Employing these criteria for rapid GES we found that 30% met these criteria while 70% had a normal GES. The GE test was performed during the remission phase of CVS. Delayed gastric emptying was not identified. Our group also published criteria for rapid gastric emptying as being <50% isotope retention at 1 hour and the majority of our adult patients (65%) with CVS had a rapid GE and 35% had a normal GE.15

A rapid or normal GE can therefore be used as confirmatory evidence of CVS so that clinicians can confidently exclude gastroparesis from the differential. Gastric emptying studies should be performed during the remission phase when there are minimal or no symptoms and no narcotic medications are being received.16-17 Gastric emptying studies while patients are in the hospital receiving narcotics are discouraged. Narcotics inhibit GE thus producing a slow gastric emptying result leading to a mislabeling of these patients as having gastroparesis. In addition, the preceding use of marijuana can delay GE. Explaining the role of a rapid GE during a vomiting free period has led to speculation and support for an underlying autonomic dysfunction is these patients as well as evidence for increased serum ghrelin as another factor in speeding up the GE.11

Diagnostic Evaluation

The diagnosis of CVS requires that other known and treatable disorders be excluded. The differential diagnosis for patients with CVS that should be ruled out includes those listed in Table 2. We recommended a diagnostic algorithm (Figure 1) through which a patient presenting with an acute episode of nausea, vomiting, epigastric abdominal pain should be evaluated so that other diagnoses can be excluded by history, physical examination, and basic laboratory studies including a complete blood count (CBC), complete metabolic panel (CMP) with liver function tests, amylase, and lipase, a urinalysis as well as an upper GI series/small bowel follow through.6 An abdominal ultrasound may help in evaluation of possible gallstones, pancreatitis and ureteropelvic junction obstruction. An esophagogastroduodenoscopy (EGD) should be performed in patients with acute vomiting with or without hematemesis to exclude gastric outlet obstruction or peptic ulcer disease as well as H. pylori. Imaging studies such as an abdominal CT should be considered to exclude structural lesions.

The decision as to which diagnostic tests to perform should be tailored to the clinical presentation of the patient. In adults, much consideration must be used to differentiate CVS from gastroparesis. A subset of patients with idiopathic or diabetic gastroparesis presents with cyclic emetic episodes similar to CVS.7 Patients with gastroparesis exhibit more chronic daily symptom severity and a delayed gastric emptying on scintigraphic study. In contrast, gastric emptying is often accelerated or normal and not delayed in patients with CVS during the asymptomatic period when vomiting is absent.7

Management

Once a cyclic vomiting episode is in progress, supportive measures are at the forefront of management. Intravenous fluids should be given to prevent dehydration and electrolyte imbalance. The approach to treatment in the ED setting is inducing sedation, sleep and relaxation mainly through IV lorazepam (1-2mg every 4 hours) with support from narcotics, anti-histamines and antiemetics to terminate the emetic phase although hospitalization is often required to achieve this goal. Family involvement is a crucial part of management in order to cope with an unpredictable, disruptive, unexplained illness that is commonly misdiagnosed.

Long term treatment of CVS is based on trying to identify the etiologic subgroups particularly the role of psychological stress while prescribing prophylactic drug and abortive therapy and supportive measures to ameliorate acute vomiting episodes. In relation to psychological stressors, stress management techniques as well as daily lorazepam (1mg up to every 6 hours) will help relieve anxiety. For the subset of patients with significant depression, co-management with a psychiatrist may be indicated to select antidepressant therapies with the least likelihood of exacerbating the emetic illness. It is appropriate to start anti-migraine prophylaxis in those CVS patients with a positive family history or personal migraine history. Anti-migraine drugs that are effective at reducing the number of episodes or severity of migraines include sumatriptan, propranolol and topamax. Patients with a history of chronic cannabinoid use should be counseled in regards to cessation that commonly leads to symptomatic improvement.4,11 Studies from our patient population have shown a high rate of cannabis use in a subset of patients with CVS. These patients need a higher dose of amitriptyline for the control of their CVS attacks compared to non-cannabis users.18-19 Therefore, it is important to identify cannabinoid hyperemesis syndrome as part of CVS, since a long term goal is decreasing and stopping cannabis use in these patients.

Long term management is focused on reducing and actually preventing future hyperemesis episodes .20-21 At the forefront of CVS management, tricyclic antidepressants (TCA), especially amitriptyline, have been shown to be effective for pharmacological prophylaxis. They are well tolerated and very effective in treating adult patients with CVS in doses of 50 to 200mg as necessary and as tolerated. Tricyclic medications act by decreasing cholinergic neurotransmission and modulating alpha-2-adrenoreceptors, thereby reducing the sympathetic nervous system and brain— gut autonomic dysfunction.13,22-23

The treatment approach with tricyclic antidepressants requires beginning with a low initial dose of amitriptyline 10 mg at night with incremental increases in 10 mg doses every 2 to 4 weeks to titrate to the desired therapeutic effect.24-25 There is no established dose to control the symptoms but prevention of the vomiting cycles is the goal. Side effects of using TCAs include dry mouth, somnolence, constipation, postural hypotension, chronic fatigue, blurred vision and mild hallucinations.24-25 Side effects can be minimized by slowly increasing the dose by 10 mg every 2—4 weeks. The rational for this approach is to identify what is the lowest dose that may be therapeutic in an individual and still limit side effects that can occur with higher doses. Tricyclic antidepressants take more than 1 month to achieve full therapeutic effect following initiation and this must be conveyed to the patient. Other TCAs such as nortriptyline and doxepin can be used as substitutes with less adverse events, but still with therapeutic benefits. More recently, the anticonvulsant agents zonisamide (100-600mg daily) and levetiracetam (500-1000 twice daily) agents have demonstrated efficacy in adult patients who are unresponsive or intolerant of TCAs, but their current role can only be considered as second line therapy.7,26

Once initial control is achieved with escalating amitriptyline dosing and concurrent lorazepam for anxiety, supportive therapy involves antiemetic agents include ondansetron, promethazine or prochlorperazine for breakthrough nausea. The antispasmodic (dicyclomine) is for irritable bowel syndrome (IBS) like abdominal pain, especially in patients with rapid gastric emptying and an exaggerated gastro-colic reflex. Proton pump inhibitors can be briefly used for gastroesophageal reflux symptoms in relation to excessive vomiting.

In our experience at a gastrointestinal motility referral center, we found that 83.3% of our patients who began on a low dose (10mg) of amitriptyline before bedtime were able to gradually escalate using an approach of 10mg increments every 2-4 weeks as tolerated and achieve symptom control as evidenced by preventing relapses and ED visits. This titration approach to the dosing of amitriptyline achieved symptomatic relief in 8% patients at a dose of 50- 75mg; 50% at 100mg; 21% at 150mg and 8% at 200mg. Nonresponse to standard therapy in adult cyclic vomiting syndrome patients occurs in approximately 13% and is not explained by under dosing with TCA therapy.24 The main risk factors for nonresponse to amitriptyline are: co-existing poorly controlled migraine headaches, psychiatric disorder, chronic narcotic and ongoing marijuana use, which should be addressed aggressively when symptom exacerbations continue during attempts to induce remission in cyclic vomiting syndrome with high-dose TCA therapy.24

Long term outcomes are now becoming apparent as treatment patterns become recognized. One pattern requires further increasing the maintenance dose overtime due to some dose tolerance slowly occurring with breakthrough vomiting cycles. Another group in whom symptoms were controlled for at least one year with no ED visits were able to be successfully tapered to a lower dose with no ED visits. The amitriptyline dose is slowly tapered or even stopped over time, usually at least 1 year. Twenty-one percent of our patients were able to reduce their dose to 10-20mg per day. One additional incentive we witnessed was a pregnancy goal in females since amitriptyline is listed as a category C by the FDA and therefore is not recommended during pregnancy.

In Summary, treatment with TCA is an effective strategy in 87% of patients and significantly decreases the frequency of attacks, number of emergency room visits and hospitalizations. Once symptoms are controlled for at least 12 months the dose of TCA can slowly be tapered to reach very low doses or even be stopped while maintaining symptomatic control. This has been a new observation, namely that effective tapering over 6 to 12 months can be achieved. The theory to explain this observation is that the CNS receptor hypersensitivity initially present in CVS patients has been successfully blocked during treatment with amitriptyline providing a time frame where the recognized risk factors of migraine, stress, diabetes, marijuana can be addressed and better controlled. Hence, the environment affecting CNS nausea receptor sensitivity has now changed so that the protective role of amitriptyline is no longer required.

CONCLUSIONS

The intent of this article was to further characterize the clinical presentation and propose new diagnostic criteria for CVS in the adult population (Table 3). CVS is not a rare condition in adults as it was once thought to be and is essentially a bedside diagnoses based on the “classic” stereotypical cycles of the vomiting episodes and discrete symptom-free intervals. It is now more common in adults than children and is diagnosed in up to 12% of patients being referred for evaluation of nausea and vomiting. As cyclic vomiting episodes coalesce, usually because no specific therapy has been given, patient symptoms can begin to resemble gastroparesis, a disorder presenting with more continuous chronic nausea and vomiting but typically much less abdominal pain. However, subsets of diabetic gastroparesis patients can have relapsing “cycles” superimposed on this chronicity and this is on example where the distinction from CVS becomes very difficult. Overall the epigastric abdominal pain is a more dominant complaint among CVS patients which is not the usual case in gastroparesis. However, rapid or normal gastric emptying in CVS may be a final “tie-breaker” in distinguishing it from the slow gastric emptying of gastroparesis.

The important message for our clinicians is that CVS can be presented to the patient as a potentially reversible disease: Following initial intensive treatment to achieve remission and after effectively addressing comorbidities, the dose of amitriptyline can be slowly tapered and even stopped over time.

Take Home Message

CVS in adults is under diagnosed and improved awareness and recognition of disease characteristics can help reduce invasive and costly diagnostic workups that have a negative effect on patient economics. This is particularly so for physicians in the Emergency Department who should have a high clinical index when a pattern of unexplained episodes of acute nausea, vomiting and abdominal pain, are observed with frequent ED visits and hospitalizations. This is the CVS “blue print” and epigastric abdominal pain should be added to the Rome criteria for adult CVS patients. Further key clinical clues for CVS lie in appreciating the comorbidities of anxiety, depression, migraine headaches and diabetics. Chronic marijuana has now become a new and very prevalent etiology and should be added as supplementary criteria. Finally, CVS patients have either a rapid or normal GE. This is a “signature” finding separating CVS from gastroparesis and we strongly recommend that GE status be added as one of the major criteria for the diagnosis of CVS.

List of Abbreviations: CVS: Cyclic vomiting syndrome; GES: Gastric emptying study; GE: Gastric emptying; ED: Emergency department; TCA: tricyclic antidepressants; PPI: proton pump inhibitors

Download Tables, Images & References

EPIDEMIOLOGY OF GASTROINTESTINAL CANCERS, #5

Dissecting the Epidemiology of Pancreatic Adenocarcinoma

Read Article

Here we discuss the epidememiology of Pancreatic cancer (PCa), the eighth leading cause of death from cancer in men and the ninth leading cause of death from cancer in women throughout the world. Delay in diagnosis, surgically inaccessible location of the pancreas, absence of classic symptoms of the disease and poverty of molecular biomarkers result in a diagnostic challenge.

1Janeesh Sekkath Veedu, MD, 1Febin John, MD, 2CS Pitchumoni, MD, 1St. Peter’s University Hospital Rutgers RWJ Medical School, New Brunswick, NJ 2Chief of Gastroenterolgy, Hepatology and Clinical Nutrition, Saint Peter’s University Hospital, New Brunswick, NJ

INTRODUCTION

Pancreatic cancer (PCa) is the eighth leading cause of death from cancer in men and the ninth leading cause of death from cancer in women throughout the world.1 The American Cancer Society estimated that 45,220 Americans will be diagnosed with Pancreatic Cancer in 2013. Delay in diagnosis, surgically inaccessible location of the pancreas, absence of classic symptoms of the disease and poverty of molecular biomarkers result in a diagnostic challenge. PCa represents 2.4% of all cancers and 3.7% of cancer deaths. Early surgical resection has a survival benefit, however, since the disease is often diagnosed at late stages surgery is not curative and adjuvant therapy becomes palliative.2

PCa is usually seen in the elderly with a male predominance, the peak incidence being in those aged 65-75 years. Adenocarcinoma accounts for 95% of all cases, about 85% are sporadic with no family history or predisposing genetic syndromes. Although 5-year survival is low (<5%), high volume surgical centers have reported survival rates of up to 40%.3 Recent studies have shown that distinct molecular subtypes of PDAC exist and are associated with different prognosis and therapy response.4 Related to improved life-expectancy and probably adoption of cancer associated lifestyles the incidence is growing globally.3

ETIOLOGICAL ASSOCIATIONS

A. ENVIRONMENTAL

Few modifiable risk factors have been implicated in the etiology of PCa.

Cigarette Smoking

Cigarette smoking is a well-established risk factor for PCa and a co-factor in chronic pancreatitis secondary to alcoholism.5 It is attributable for about 20-30% of cases of PCa.6-13 Studies report a higher risk among current smokers compared to non-smokers, up to 6 fold depending on duration and intensity of cigarette smoking,14 (RR=1.74, 1.61—1.87) and also in former smokers with respect to never smokers (OR=1.20, 1.11-1.29).7,9 Smoking 1 pack/day increased the risk by 1% and the risk doubled for those with >40 pack years of smoking.7 Pipe/cigar smoking had lower risk when compared to cigarette smoking but passive smoking (workplace/household) did not increase the risk.12 Though the risk remained elevated for up to 15 years after quitting, a non-significant drop in risk was observed after 20 years.7,9

Cigarette smoke contains nearly 4000 chemicals of which more than 60 has been identified as carcinogens14 (polycyclic aromatic hydrocarbons, N-nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes and ethylene oxide). The toxins reach the pancreas indirectly via bloodstream or biliary regurgitation to exert carcinogenic effect.8,11,15 Recent studies have looked into genetic variations at carcinogen-metabolizing enzymes to further understand individual susceptibility to PCa.15 Of the carcinogens the most potent metabolite, NNK mediated pathways is well studied.14 There have been no major studies on the effect of e-cigarettes on PCa. E-cigarette users were more nicotine dependent than nonusers, had more prior quit attempts, and were more likely to be diagnosed with thoracic and head or neck cancers.16

Alcohol

An association between alcohol abuse and pancreatic injury was reported by Friedreich as early as 1878.17 Freidreich recognized an association of alcohol abuse with chronic pancreatic injury.17 Several studies have evaluated the association of alcohol and PCa but conclusive evidence is lacking.11,17-21 This could be due to interplay of significant confounders such as smoking, pancreatitis, nutritional and genetic factors.17,21 However, alcohol has been projected as an independent risk factor, attributable to 2-5% of all PCa cases (where population prevalence of heavy drinking is 10-15%).11,17,21 Heavy drinking (>40g or >3drinks/ day) is associated with moderate risk (RR=1.22, 1.12- 1.34) in women and up-to 3.5-fold risk in male binge drinkers (>70g or >5 drinks/day).17,19,21 The risk with type of beverage consumed (wine, beer, liquor/spirit) is variable but an increased risk with the duration of alcohol consumption is reported.18,19

The causal role of alcoholic pancreatitis which is responsible for <5% of PCa cases is not adequate enough to explain the link between alcohol and this PCa.21 Acetaldehyde (oxidative pathway) and fatty acid ethyl esters (non-oxidative pathway), the metabolic products of alcohol, activate pancreatic stellate cells leading to inflammation, immune response and cancer.17,21,22 Folate depletion leading to defective DNA synthesis/repair and carcinogen activation via induction of cytochrome P450 is also postulated means of alcohol injury.18

Diet

The role of diet in the pathogenesis of PCa is weak and contradictory. Mediterranean diet rich in plant-based foods, whole grains and fish with modest consumption of meat and dairy products was associated with a decreased risk (OR=0.51, 0.31-0.84).23-26 A 2.4-fold risk was reported in men on a Westernized diet (red/processed meat, potato, sugary beverage, refined grains, eggs and high-fat dairy).24 Red meat consumption was associated with an increased risk in men.27 A statistically significant 19% higher risk in those consuming processed meat (50g/day) was reported in a meta-analysis.27 Energy- dense diet consumption escalated the risk (up to 72%) while soft drinks did not.28,29

Although dietary fat is not associated with increased risk, a recent study attributed a diet rich in cholesterol with low fiber and folate to the increased incidence of PCa in Poland.30,31 Dietary magnesium especially in overweight men is found to decrease the risk (18% reduction with 100mg increased intake) and cruciferous vegetables (OR=0.90) were protective.32,33 There is no protective effect for antioxidant consumption while a 2-fold risk is seen in those with high serum levels of 25 (OH) vitamin D (=100 nmol/L).34,35 Based on data from the European Prospective Investigation into Nutrition and Cancer Cohort, coffee (total or decaffeinated) and tea consumption are not related to the risk of PCa.36

Occupation

Certain occupations are associated with an increased risk, especially with exposure to chlorinated hydrocarbons and polycyclic aromatic hydrocarbons (PAH).37 Dry-cleaning, metal-related work (Gold/silver smith) and electronic work have exposure to chlorinated compounds.37 Although an increased risk with herbicide and fungicide (not insecticide) was noted in one US study, others failed to demonstrate this risk.37,38 PAH associated risk was seen among metal workers and those in aluminum industry.37,39 Occupational exposure to inorganic dust, asbestos and ionizing radiation also amplified the risk.37,40 Assessment of PCa risk among night shift workers in Japan and food industry workers in Finland did not yield significant result except in Finnish males (SIR=1.5, 1.13-1.96).41,42

Exposure To Heavy Metals

There are reports in literature to support the risk for PCa from exposure to heavy metals. Higher incidence of PCa in the East Nile delta region of Egypt is now attributed to cadmium exposure from fertilizers and polluted river water.43,44 An epidemiological study from Louisiana reported this heavy metal exposure from food (pork, seafood, rice) as the cause of increased incidence of this cancer among the Cajuns.45 Cigarette smoke is another potent source of cadmium which could be implicated for the increased risk of PCa among smokers.45 Cadmium exerts its carcinogenic effect via impairment of DNA repair mechanisms to cause genomic instability.44

Arsenic with similar carcinogenic mechanism is also incriminated in PCa.44 A recent study from Florida reported a significant increase in the risk among those living within 1 mile radius of Arsenic-contaminated wells.46 There are reports about childhood arsenic exposure (from milk powder) and increased mortality associated with this cancer.44,47 Although asbestos exposure from drinking water was reported to increase PCa, subsequent follow-up and analysis failed to prove this.48 Similarly there are studies, which link exposure to lead and decreased levels of selenium (toenail concentrations) to PCa.44

Radiation

In a study of the Hiroshima and Nagasaki, the two sites of atomic bombings, no radiation effect was noted.49 However one study showed excess deaths from PCa in patients who received therapeutic irradiation for ankylosing spondylitis50 and another reported two cases of PCa in patients who got abdominal radiation for testicular cancer.51

Infection

Studies have revealed an infective etiology of PCa, the main agents being H pylori, HBV, HCV and HIV.

H pylori, extensively studied as a gastric carcinogen is being investigated for extra-gastric associations. Several studies including a meta-analysis have found significant association of PCa (AOR=1.38, 1.08- 1.75) with this highly prevalent infection (40% in developed countries and 70% in developing countries) and about 2-fold risk with CagA +/ VacA + strains.52,53 The antral colonization of H pylori and subsequent hyperchlorhydria leading to increased pancreatic secretions and hyperplasia is one of the plausible mechanisms.52,54 Inflammation (IL 8 and VEGF) and bacterial overgrowth from hypochlorhydria (increased N nitrosamine) are other suggested mechanisms.52-54

An increased risk was seen with active (RR=3.83), chronic (RR=1.39) and past (RR=1.41,1.06—1.87) HBV infection.55 There was a synergic increase in the risk in chronic/inactive HBsAg carriers with DM.56 HCV with mechanisms similar to HBV was found to double the risk for PCa (SIR=2.1, 1.4, 2.9).57-59

There is an increased incidence of PCa in HIV patients (SIR=2.2, 1.2-3.6).60 PCa was diagnosed at a younger age with advanced stages at presentation and had a higher likelihood of unfavorable performance status in HIV positive subjects.61 Periodontal disease, and Porphyromonas gingivalis, a pathogen for periodontal disease, are reported associations in PCa.62

B. CHRONIC PANCREATITIS

All types of chronic pancreatitis predispose to PCa (RR=5.1, 3.5-7.3), although <10% is attributed to it.63,64 A significant risk was associated with both acute (HR=9.1, 3.81-21.76) and chronic pancreatitis (RR=13.1, 6.1-28.9).63,65,66 Different forms of chronic pancreatitis such as hereditary, autoimmune and tropical pancreatitis are discussed in literature, all of which are significantly associated with PCa. Patients who underwent surgery for the treatment of chronic pancreatitis had significantly lower incidences of pancreatic cancer. Surgery for chronic pancreatitis may inhibit the development of pancreatic cancer in patients with chronic pancreatitis.67 Acute pancreatitis may be an initial manifestation of PCa.

1. Hereditary Pancreatitis (HP)

Hereditary Pancreatitis (HP) is an inherited form of chronic pancreatitis characterized by recurrent episodes of pancreatitis since childhood.68-71 Mutation in the cationic trypsinogen gene (PRSS1) was the first identified genetic defect.68,71 Subsequently several germline mutations such as protease serine 2 (PRSS2), pancreatic secretory trypsin inhibitor (SPINK1), CFTR, chymotrypsinogen C (CTRC) and calcium-sensing receptor (CASR) were discovered.68 Individuals with HP have a high risk for PCa (SIR=87, 42-114).69,70,72 The cumulative risk by age of 75 years is about 40%- 53.5%.69,70,72 Smoking and diabetes further increased the risk in these patients.71

2.Tropical Calcific Pancreatitis (TCP)

Also known as fibrocalculous pancreatic diabetes (FCPD), Tropical Calcific Pancreatitis (TCP) is a form of chronic pancreatitis in Afro-Asian countries.73,74

The exact etiology for this form of chronic pancreatitis has not been established. Studies have clearly shown that this is a high risk factor for PCa (RR=5, 1.03-14.6).73,75 Patients who develop PCa are younger compared to the denovo form. The entity although found in many states in India is well studied in large series of patients mostly from states of Kerala and Tamil Nadu.

Early studies identified TCP as a disease in young malnourished individuals with poor prognosis leading to diabetes and having a high risk for PCa. But recent research found strong genetic links to this disease (SPINK1/CFTR mutations) and dismissed the notion of regional predominance, links to nutrition and grave prognosis.76,77

The pathogenesis of malignancy in pancreatitis is postulated via inflammatory mediators, activation of signaling pathways (cyclooxygenase2 expression, Notch signaling, Hedgehog signaling) and oxidative damage.66,67 Ueda et al. reported a decreased risk in chronic pancreatitis patients managed surgically (HR=0.11, 0.014-0.80) which provides further evidence for the inflammatory etiology.67

3. Autoimmune Pancreatitis

Autoimmune Pancreatitis is a steroid responsive type of chronic pancreatitis, which mimics PCa.78-80 Although several case reports have been published, conclusive evidence regarding its association with cancer is lacking other than an increased occurrence of K-ras mutations.78-80 AIP features a significant inflammatory phase, and hence it is biologically plausible that AIP patients are similarly at increased risk for developing PCa. The potential for systemic inflammation in this multiorgan disease could also contribute to risk for extra pancreatic cancers. Finally, the late age at presentation of type 1 AIP and reports of cancer being discovered shortly before and after AIP diagnosis have fueled speculation that AIP is a paraneoplastic manifestation of an underlying cancer.81

C. DIABETES AND PANCREATIC CANCER

This is a clinically important but controversial topic. Type 2 Diabetes (DM) with its temporal association with PCa is described both as cause and result of the cancer.82-84 This is an independent risk factor with approximately two-fold increased risk compared to general population.82,83 Risk is inversely associated with the duration of DM, the highest risk being with <1year of DM (OR=5.38;3.49—8.30).83 No increased risk was seen in subjects with >9 years of DM (OR=1.02; 0.68- 1.52) which contradicted the findings of a previous meta-analyses.82,85,86 The association between DM and PCa was not modified by gender, smoking, age, or BMI.82 History of diabetes in a first degree relative increased the risk (OR=1.37, 1.10-1.71) per the PACIFIC study (pancreatic cancer: investigation into finding causes).87 A meta-analysis observed equal risk in diabetic men and women but some disparity exists in this regard.83,84,88 Higher risk was seen among those using insulin compared to those without (OR=3.34 vs. 1.50) in the Iowa Women’s Health Study (IWHS).84

Hyperglycemia associated with altered glucose metabolism, chronic inflammation, oxidative stress, and activation of insulin signaling cascades increases the risk of pancreatic cancer.89 The development of DM within a few years of a pancreatic cancer diagnosis is more likely to suggest an effect of the tumor, whereas diabetes of longer duration is more likely to contribute to the development of cancer.90

However in a study from Japan, PCa was diagnosed within 2 years of DM onset (new-onset) in 0% of the patients with early-onset DM, and in 33% of those with late-onset DM. Pre-existing type 2 diabetes, acute alcoholic hepatitis, acute pancreatitis, cholecystitis, and gastric ulcer independently or jointly predict subsequent pancreatic cancer risk.91

The notion that new-onset diabetes in pancreatic cancer is a paraneoplastic phenomenon caused by tumor secreted products was strengthened by a recent study that proposed adrenomedullin, a 52 amino- acid polypeptide, as a strong candidate for mediator of diabetes in pancreatic cancer. Adrenomedullin was also shown to be overexpressed in human pancreatic cancer and plasma levels of adrenomedullin were also increased in pancreatic cancer patients, especially those with diabetes.92 Earlier concept of beta cell destruction has given way to the role of hormonal secretions from the tumor causing insulin resistance, up-regulation of IGF- 1 leading to carcinogenesis via enhanced angiogenesis and cell growth without apoptosis.82,83,89 Supported by the fact is the observation that IGF receptor and insulin receptor substrate-2 (IRS-2) are over-expressed in cancer cells of the pancreas.93 Other+ studies have shown the presence of diabetogenic factors (2030 MW peptide, Amylin/IAPP) in the serum.83,94 Thus patients with new-onset DM with a family history of DM should be screened for underlying malignancy.87 Similarly new-onset DM in older patients (>65 years) with a negative family history and low BMI (<25) or recent weight loss (>2kg) also have a likelihood for associated PCa.95 Reducing diabetes by controlling obesity could benefit pancreatic cancer rates, in addition to the many other known health benefits.82 One study showed that dyslipidemia, but not diabetes, is a significant risk factor for PCa. Patients with new-onset diabetes and a history of dyslipidemia are at an especially high risk of PCa.96 DM is also an independent risk factor for liver, colorectal and breast cancers but decreases the risk of prostate cancer.97

The use of metformin, the most commonly prescribed drug for type 2 diabetes, was repeatedly associated with the decreased risk of the occurrence of various types of cancers, especially of pancreas and colon and hepatocellular carcinoma.98

D. OBESITY

Obesity, a rising epidemic, has association with multiple cancers99-101 and has been discussed in detail in an earlier paper in this series. Most of the studies have found an association of increased BMI (marker of obesity) with PCa (RR=1.2-3).84,102,103 A meta-analysis observed 19% increased risk in obese people (BMI>30 kg/m2).101 Obesity related PCa had a population attributable fraction of 26.9% and 19.3% in US and EU respectively.102,104 An earlier age of onset was seen in those who were obese/ overweight during their adolescence (HR=2.09, 1.25- 3.50).102,105 Similarly in the elderly, obesity was found to reduce survival in PCa patients.102 Metabolic syndrome (MetS) is associated with many more consequences than generalized obesity. MetS was found to be associated with PCa in both men (SIR=178,144-266) and women (RR=1.58, p<0.0001).106,107 MetS components were also found to increase the risk [fasting blood glucose (OR=4.24), total cholesterol (OR=1.79), apolipoprotien A (OR=36.06)].108 One European study reported significant risk with several metabolic factors in women (mid-blood pressure, glucose, triglycerides, BMI).109

Physical activity was found to decrease the risk [e.g.: history of sports (HR=0.80, 0.64-0.99), occupational physical activity (RR=0.75, 0.58-0.96)].103,110 Release of cytokines (IL-6, TNF a, CRP) leading to insulin resistance and higher insulin levels result in increased IGF-I: IGFBP-3 (insulin growth factor and binding protein ratio) is probably related to carcinogenesis in obesity.101,106,111

INHERITED PANCREATIC CANCER

Genetic predisposition accounts for 5-10% of all pancreatic cancers.72,87,112,113

Familial pancreatic cancer (FPCA) -is defined as a family with more than one first degree relative (FDR) with history of PCa without any inherited syndromes.112 A 2.3 to 4.5-fold increased risk with 1 FDR, 6.4-fold with 2 FDRs and up-to 32-fold with =3 FDRs with pancreatic cancer has been noted.72,114,115 FPCA which is influenced by race (Ashkenazi Jews), smoking and diabetes, and genetic anticipation (younger age or worse prognosis with successive generations).72 Pancreatic intraepithelial neoplasia with mutations in the K-ras (codon 12) was more frequently (2.75 fold) observed in familial pancreatic cancer when compared to sporadic.72

Hereditary pancreatic cancer- is a genetic syndrome with mutations that increase the risk for PCa.112 Peutz- Jeghers syndrome with STK11/LKB1 gene mutation is associated with up-to 132-fold increased risk for PCa.72,112,116,117 Hereditary Non Polyposis Colon Cancer (HNPCC) is associated with a lifetime risk of 1.3-4% for PCa.112 Majority of the Hereditary Breast Ovarian Cancer (HBOC) is due to mutations in BRCA1 and BRCA2 genes.112 The risk for PCa in BRCA1 carriers is minimally elevated compared to general population (RR=2.8 vs. 1.3%).112 BRCA2 mutation has a 5-7% lifetime risk in carriers and is the most common inherited gene for development of PCa.112 Families with Familial Atypical Multiple Mole Melanoma syndrome (FAMMM) are at increased risk (13-22%) for this cancer.72,112 Individuals with p16/ CDKN2A (FAMMM gene) mutation have a 38-fold higher risk in comparison to general population.72 Studies have shown a mild elevation of risk in FAP with APCA gene mutation (RR=4.5), Cystic fibrosis (CFTR gene) and Ataxia telangiectasia (ATM gene).72,112,116 Associations of PCa with PALB2 (partner and localizer of BRCA2) and palladin (cytoskeleton associated protein) mutations are being observed.72,116,118. (See table X)

OTHER FACTORS

Several studies among different populations across the world have reported an increased risk associated with non-O blood groups for PCa (OR=1.37, 1.02- 1.83).59,119-121 Mechanisms though not clear; relevance of physiological differences in inflammatory mediators (TNFa, cellular adhesion molecules) is being postulated.119 Few studies have found a significant co- relation of this disease with a history of cholelithiasis (HR=3.12, 2.05-4.78) and cholecystectomy (higher prevalence 6.2% vs. 2.9%).108,122 Anti-diabetic medications and NSAID’s are found to have an effect on PCa risk. Metformin (HR=0.73, 0.66—0.80) and thiazolidinediones were associated with reduced risk but insulin (HR=4.63, 2.64—8.10) and sulphonylureas (HR=4.95, 2.74—8.96) aggravate the risk.123-125 DPPV IV inhibitors (sitagliptin) have a theoretical risk for carcinogenesis126 but a recent meta-analysis on this issue reported conflicting results.127

Although not conclusive enough, there is evidence to suggest that high-dose aspirin reduces the risk for PCa (OR=0.78, 0.64-0.95).128-130 Similarly there is lack of satisfactory evidence for other NSAIDs.130 A combination of aspirin, curcumin and sulphoraphane has been found to be beneficial against PCa in animal studies.131 One study from Netherlands observed an inverse association of PCa with hypertension.132 Metformin offers a potential novel approach for pancreatic ductal adenocarcinoma prevention and therapy.133

ALLERGIES

A recent meta-analysis reported 30% drop in pancreatic cancer risk among those with history of allergies.134 Statistically significant risk reduction was observed with hay fever (OR=0.74, 0.56-0.96) and allergy to animals (OR=0.62, 0.41-0.94).134,135 Other allergies, such as those to foods and medications, have been less well studied and associations with risk are unclear.136 Heightened immune surveillance is suggested as the plausible explanation.

GLOBAL EPIDEMIOLOGY

The annual incidence and mortality of PCa is the same (ASR incidence =7.2 vs. 2.8 and ASR mortality=6.8 vs. 2.7).137 Analysis of global data based on human development suggest a higher incidence in areas with high human development (ASR incidence= 4.6) as opposed to areas with less development (ASR incidence= 1.2) (Fig-1).137 Although reasons are not fully elucidated, it is linked to human lifestyle and diet. Immigrant studies, which found increased risk among Indians who migrated to Australia and UK, support this observation.138,139 The highest incidence for women is reported in North American and northern Europe. A high incidence of PCa in Ashkenazi Jews140 and a lower incidence among the Utah Mormons141 has been noted. A brief summary of the incidence of PCa in different parts of the world is given below.

A. AMERICAS

North America, with isolated exceptions, has the highest incidence and mortality for PCa in the world (Incidence ASR= 7.4 and mortality= 6.9) (Fig-1).137 Even though rates in South America are lower, French Guyana and Uruguay are ahead of US and Canada.137 Lowest estimates are seen in Guatemala, Haiti, Panama and the Bahamas (Central America).137

Although PCa ranks only 13th among cancers, it is the 4th major cause of cancer-related death137 with a 5-year survival rate of 6%.142 Blacks have a higher incidence (33% more) and mortality (32% more) than Whites.143 Asia Pacific Islanders have the lowest rates and better survival.142 The rates for the indigenous groups fall between the Blacks and Asia- Pacific Islanders.142 This racial disparity could not be attributed to any of the known risk factors (smoking, BMI, family history, diabetes and cholecystectomy).143 Latitudinal variation in the incidence and mortality of this cancer was attributed to solar UV-B exposure.144

B. EUROPE

Western Europe, Central and Eastern Europe have higher incidence (ASR=6.6-7.3) and mortality (ASR=6.6-6.8) for PCa compared to Northern and Southern Europe (Fig-1).137 Highest incidence is seen in Czech Republic, Slovakia, Hungary, Slovenia and Finland with Czech Republic having the highest incidence rate in the world (ASR=9.7).137 Sweden, Albania, Cyprus and Bosnia have the lowest rates. Hungary has the highest mortality rate for PCa in Europe (ASR=8.8).137

The overall cancer mortality with the exception of PCa has decreased in this region since 1980.145,146 A higher incidence was reported among people living in most deprived areas, partly linked to high prevalence of smoking.146 In England, total number of cases was higher in Whites compared to Non-Whites (South-Asian, Blacks, Chinese 17% of population). However, age standardized incidence was higher in Blacks (ASR=5.7 in Blacks vs. 4.9 in Whites).139 The risk was lower in South-Asians compared to Whites while no significant risk was demonstrated in Blacks and Chinese.139 Immigrant population in England (non- White) had higher incidence of this cancer compared to their counterparts living in homeland.139 A 138% increase in incidence of PCa was reported in the Inuit population (SIR=2.38, 1.97-2.86; p<0.0001) plausibly due to the high prevalence of diabetes and smoking.147 Even though a Nordic country, Finland has a high incidence of PCa (ASR=8.7).137 This is the 5th most fatal cancer in the country (ASR=7.8).137 The 5-year survival has not improved much over the past 50 years (from 3 to 5%).148 Although coffee consumption is very high, it is not associated with an increased risk for PCa (HR=0.82, 0.38-1.76).149

C. ASIA

Eastern Asia (People’s Republic of China, Japan, North Korea, South Korea, Mongolia and Taiwan) followed by Western Asia (Armenia, Azerbaijan, Middle East, Cyprus, Sinai Peninsula of Egypt, Georgia, Turkey) has the highest incidence of PCa in Asia (ASR=4.5 and 3.9 respectively) (Fig-1).137 Similar is the trend in mortality (ASR=4.3 and 3.8 respectively). The Central and South- East Asia have lower rates (Fig-1).137 Highest mortality rate for PCa is in Armenia worldwide (ASR=8.9). Also Armenia has the highest incidence and mortality in this continent followed by Japan, Israel, Kazakhstan and Korea.137 Lowest rates are seen in India, Nepal, Bangladesh, Pakistan and Sri Lanka.137

1. Japan

PCa has a high incidence in Japan (ASR=8.5) and is the 5th common cause of cancer-related mortality in both men and women (ASR=9.5 and 6.1 respectively).137 Although the 5-year survival is around 5%, resected cases have better prognosis (5-year survival=18.8%).150 Positive family history and presence of diabetes were reported as major risk factors apart from smoking.151 Northern Japan has a higher mortality from this cancer as opposed to south which was linked to variations in exposure to solar irradiation and temperature.152 A high non-linear relationship of PCa death with low- dose external irradiation (<20mSv) was reported in Japanese-A bomb survivors.153

2. Korea

With a high incidence (ASR=6.7), PCa in Korea is the 5th most fatal cancer (ASR=6.2).137 Analysis of trends in incidence from 1999-2010 showed that PCa is increasing in Korea (APCA in both sexes=1.4) with a greater increase in women (APCA=2.2 vs. 0.6 in men).154 Although hepatitis B is endemic in Korea, it was not found to increase the risk for this malignancy (OR 1.03, 0.69-1.53; p=0.91) as opposed to hepatitis C (OR=2.30, 1.30-4.08; p< 0.01) and non-O blood group (OR=1.29, 1.05-1.58; p=0.01).59

3. China

The incidence of PCa is not very high in China (ASR= 3.6) but it is the 8th most common cause of cancer related death.137 Cigarette smoking (44%), pancreatitis (16%) and family history of PCa (8%) were the major etiologies in young patients with PCa.155 Incidence of diabetes among PCa patients was much higher (34.6% vs. 8.8%) and 74.56% (in the cancer group) had onset of DM within 2 years of diagnosis of cancer.156 Energy dense foods increased the risk (OR: 1.72; 95% CI: 1.25, 2.35; P = 0.001) in Chinese.28 Regular green tea drinking was found to be protective in Chinese women (OR 0.68, 95% CI 0.48—0.96).157 For reasons not clear, in one study acute pancreatitis patients had a high risk of developing PCa within 5 years of index pain (HR=9.10; 3.81-21.76).66

4. India

India has a low incidence (ASR=1.2) and mortality (ASR=1.1) for PCa.137 Recent studies note an increasing incidence of PCa in both men and women.158 A greater risk was observed in educated males with about 3-fold risk in those with >12 years of education.159 Tropical calcific pancreatitis, which has a very high risk for this cancer (RR=100, 37-218), is highly prevalent in some parts of India.73,75

5. Israel

PCa in Israel ranks 3rd in men (ASR=8.6) and 4th in women (ASR=6.2) in malignancy related deaths.137 Jews had a higher incidence than Arabs (ASR males 7.45 vs. 5.61) with the highest incidence (ASR males 8.11 vs. 7.45) in immigrant Jews (European-born).160 Nevertheless, a decreasing trend is seen in the Jewish population160 Mutation in BRCA1/2 was the major cause of this cancer in Ashkenazi Jews.161

D. AFRICA

The southern part of the continent, which includes South Africa, Mauritius and Zimbabwe, has the highest estimates for PCa in Africa (ASR incidence=4.3, ASR mortality=4.2) (Fig-1).137 Libya and Egypt, though in the northern part has incidence and mortality rates similar to Southern Africa.137 There are few studies, which attribute pollution of the Nile for the increased incidence in Egypt.43,162 Serum cadmium is suggested as the etiologic agent for the occurrence of early- onset PCa in the East Nile delta region.43 A Moroccan study reported higher incidence (17%) of pancreatic adenocarcinoma in adults <45 years (3% in the US) which did not correlate with smoking, alcoholic pancreatitis or family history.163 Lowest incidence (ASR<2) and mortality (ASR<1.9) for this malignancy is seen in Malawi, Guinea and Tanzania.137

E. OCEANA

Australia has the highest incidence (ASR=6.6) of PCa in this region followed by New Caledonia (ASR=6.5) and New Zealand (ASR=5.9) while island countries such as Samoa and Vanuatu have the least (Fig-1).137

1. Australia

PCa is the 5th common cause of cancer-related death in Australia.137 A rise in incidence (ASR 7.67 to 8.24) and mortality (ASR 7.02 to 7.58) of PCa was observed in women (from 1977-2006) while these estimates dropped in men164 attributed to variation in smoking habits.164 An interesting observation is that mortality from PCa was 9% less in Brisbane (Queensland) when compared to Melbourne (Victoria), which was linked to variations in UV exposure between the two capital cities.165

2. New Zealand

PCa is the 5th most fatal cancer in this country.137 A higher incidence and worse prognosis was reported among the Maori tribe which was attributed to smoking.166 Blakely et al. analyzed cancer incidence in New Zealand by dividing the population into 4 ethnic groups (Maori, Pacific, Asian and European/others) and found a 1.5-times higher rates for PCa in the Maori and Pacific groups compared to the European group.167

CONCLUSION

PCa continues to be a major clinical challenge because of a trend in increase in incidence with no major improvements in survival. Recent studies have reported miRNA-21, c-Myc, L-type amino acid 1 transporter (LAT1), K-ras codon 12 mutation, p38? Mitogen-activated Protein Kinase and SMAD4 as biomarkers in predicting prognosis and survival in these patients.168-174 Circulating Tumor Cell (CTC) detection in peripheral blood with a diagnostic accuracy of 70% (EUS-FNA=85%) is a promising noninvasive early diagnostic procedure.175 A study from MD Anderson, Texas reported an association between NAFLD and pancreatic cancer.175 If this observation is confirmed in further studies, it is concerning since MetS and obesity are rapidly increasing. Furthermore they observed simultaneous pancreatitis and liver cirrhosis in obese pancreatic cancer patients providing additional evidence for the role of obesity.175

Endocrine (islet cell tumors) and rare non-endocrine tumors (acinar cell carcinoma, adenosquamous carcinoma, colloid carcinoma, giant cell tumor, hepatoid carcinoma, intraductal papillary-mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma) of the pancreas are not discussed in this article.

Regardless of the advances in medical science, PCa remains a challenge. More desirable survival outcomes rely on novel research that focuses on finer diagnostic and therapeutic approach, yet to materialize.

Download Tables, Images & References

A CASE REPORT

Bezoar in a Periampullary Duodenal Diverticulum Causing Pancreatobiliary Obstruction

Read Article

In this case, we report a bezoar filling a duodenal diverticulum causing obstruction of the pancreatobiliary tree in a patient presenting with severe epigastric pain. Duodenal diverticula are typically asymptomatic outpouchings that form due to chronic duodenal ulcers or laxity of the bowel wall around the ampulla. When symptomatic, patients usually present with abdominal pain caused by duodenitis. People with gastroparesis, prior gastric surgery or a large diverticulum are at increased risk of forming a bezoar that can lead to gastric, small bowel, biliary or pancreatic duct obstruction. In a patient presenting with epigastric pain, laboratory results and cross sectional imaging are the quickest and easiest way to help make the diagnosis of an obstructing bezoar. Treatment options include conservative management, endoscopy or surgical removal of the obstructing mass.

Javier Rivera, MD, PGY-3, Diagnostic Radiology Paul Klepchick, MD, Diagnostic Radiology, Division of Abdominal Imaging Deepti Dhavaleshwar, MD, PGY-5, Department of Gastroenterology Allegheny General Hospital, Pittsburgh, PA

A 56 year old female with a 40 pack-year smoking history and a past medical and surgical history of depression, appendectomy and cholecystectomy presented with abdominal pain and 3-4 episodes of nonbloody and nonbilious emesis. She was hospitalized 3 times over the course of 3 weeks for pancreatitis at an outside hospital. Outside images were not available, however, a magnetic resonance cholangiopancreatography (MRCP) performed one month prior to the current presentation reported extrahepatic and intrahepatic ductal dilation, without choledocholithiasis. A planned endoscopic retrograde cholangiopancreatography (ERCP) was cancelled at the patient’s discretion. A chest computed tomography angiogram (CTA) was performed on a prior hospitalization due to symptoms related to congestive heart failure or possible pulmonary embolus. The CTA reported no pulmonary embolus; however, it did report small bilateral pleural effusions, bibasilar atelectasis and moderate emphysema. On the current admission, her symptoms included sharp and constant epigastric pain radiating to her back, rated 10/10 that was relieved by narcotics. She denied fevers and abnormal bowel movements. Vital signs at presentation were: temperature 37.1, heart rate of 75 bpm, blood pressure of 117/67 mmHg, respiratory rate 17, oxygen saturation 97% on room air. Physical exam revealed a neurologically intact, slightly jaundiced female in mild discomfort. The abdomen was non-distended and bowel sounds were noted in all four quadrants. The abdomen was tender in the epigastric region to light and deep palpation. No rebound tenderness was noted, nor ascites, palpable mass or costovertebral angle (CVA) tenderness. Laboratory findings include alanine aminotransferase level of 472 U/L, alkaline phosphatase level of 832 U/L, aspartate aminotransferase level of 275 U/L, lipase level of 1461 U/L, total bilirubin level of 2.9, WBC level of 12.2 k/mcL.

A CT scan of the abdomen and pelvis was performed and the patient was referred to the gastroenterology service. The patient was given one dose of 400mg ciprofloxacin and 500mg of flagyl in the emergency department due to the mildly elevated white blood cell count and was continued on the same antibiotic regimen when admitted. She was placed on narcotics and anti- emetics and was scheduled for an ERCP.

Radiographic and ERCP findings

The CT scan showed an obstructing bezoar within a 4.0 x 3.7 cm periampullary diverticulum causing severe intrahepatic and extrahepatic biliary dilatation, pancreatic duct dilatation and mild fat stranding surrounding the pancreatic head (Figures 1-2). Differential diagnosis included duodenal diverticulitis/ abscess or obstructing malignancy.

The ERCP showed two diverticula at the major papilla. The papilla was at the rim of a single diverticulum, which was ulcerated and impacted with solid food (Figure 3). The majority of the food was removed using a tripod and multiple flushes through a cannula. After clearance of the bezoar, a gush of bile followed the relief of the obstruction. Sphincterotomy was not performed due to the edema caused by the bezoar. The patient improved after treatment.

A follow up ERCP was done at 5 weeks. A single peri-ampullary diverticulum with a small opening was found at the major papilla, without evidence of bezoar impaction. The biliary duct was cannulated with a 44 sphincterotome. Severe, diffuse dilation of the biliary tree was present, with the CBD measuring 15mm. A balloon sweep of the CBD was performed using a 15- 18mm balloon, without evidence of stones, sludge or debris. An endoscopic ultrasound (EUS) was also performed at this time, which revealed a normal pancreas and pancreatic duct, with no evidence of divisum. Follow up laboratory values also improved. Alanine aminotransferase level of 14 U/L, alkaline phosphatase level of 115 U/L, aspartate aminotransferase level of 18 U/L, lipase level of 85 U/L, total bilirubin level of 0.3, WBC level of 10 k/mcL.

DIAGNOSIS

Periampullary duodenal diverticulum with bezoar causing pancreatobiliary obstruction.

DISCUSSION

The most common causes of biliary obstruction is a common bile duct stone. Other causes include pancreatic carcinoma, cholangiocarcinoma, stricture of the CBD, infection or recent instrumentation.

A search of the current literature3-6 revealed that bezoars are uncommon sources of bowel obstruction, and are more rare causes of pancreatobiliary obstruction and acute pancreatitis. A bezoar is an indigestible mass that commonly develops in the stomach; however, they can also form in the small bowel. Categories of bezoars include phytobezoar, made predominantly of plant matter; lactobezoar, made of undigestible milk; pharmacobezoars, made of medications; and trichobezoars, found in people with tricotillomania who present with an obstructing conglomeration of hair in Repunzel syndrome. People with prior gastric surgery and gastroparesis are at increased risk of bezoar formation.5 Surgeries that bypass the pylorus may cause large food boluses to enter the small bowel, which could potentially cause small bowel obstruction. Stasis of foodstuff in the stomach, or in this case, a diverticulum, may also predispose people to forming bezoars and obstruction. Treatment of bezoars in the stomach and duodenum include ERCP or surgery, if the bezoar cannot be removed with a net or basket. If the bezoar is causing a small bowel obstruction, patients are managed surgically with enterotomy.

A recent case report described bezoar-induced pancreatitis secondary to a bezoar in a periampullary diverticulum, however there was no biliary obstruction.7

A periampullary diverticulum contains or is adjacent to ampulla of Vater, while a juxtapapillary diverticulum originates within 2cm from the papilla. Diverticula may form due to wall weakness where the common bile duct (CBD) and pancreatic duct (PD) attach to the duodenum or with increasing age. Duodenal diverticula are typically asymptomatic, and are found incidentally in 6% of Upper GI studies and up to 23% at autopsy.1 They can, however, cause sphincter of oddi incompetence, abdominal pain, jaundice, bleeding, biliary stones, diverticulitis, perforation and pancreatic or CBD obstruction. In our case, the diverticulum filled with a food bolus. Cross sectional imaging with oral and intravenous contrast has helped in the detection of air fluid levels within the diverticulum, identifying the diverticular neck and sequela of possible obstruction of the small bowel or pancretobiliary system.7


Treatments of periampullary diverticula include
conservative management, endoscopy or surgical
removal.

Download Tables, Images & References

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #137

Clinical Observations Correcting Hypernatremia: Enteral or Intravenous Hydration?

Read Article

Carol Rees Parrish MS, RD, Nutrition Support Specialist, Digestive Health Center of Excellence, Mitchell H. Rosner, MD, Henry B. Mulholland Professor of Medicine Chairman, Department of Medicine, Division of Nephrology, University of Virginia Health System, Charlottesville, VA

BACKGROUND

Hypernatremia is defined as a serum sodium value > 145 mEq/L. Since the serum sodium is determined by the ratio of the amount of sodium in the serum to the amount of plasma water, hypernatremia can develop from either an excess of sodium (such as due to the administration of hypertonic fluids), a loss of hypotonic fluids (free water) or a combination of both. Most commonly, it is the loss of hypotonic fluids and the failure to replace these water losses that result in hypernatremia.

In most circumstances, thirst is a powerful defense mechanism against a rise in the serum sodium level. The body defends its serum osmolality closely so that as the serum sodium rises (and with it serum osmolality), thirst ensues along with rises in arginine vasopressin (AVP) secreted by the posterior pituitary. AVP leads to urinary concentration and conservation of renal water excretion, but ultimately it is thirst and ingestion of water that allows the serum sodium to normalize. Thus, most patients who develop hypernatremia have the common feature that water intake is restricted in some form. For instance, patients in the intensive care unit (ICU) who are intubated and sedated cannot control their water intake and the same is true for patients with impaired mental status or limited mobility. Thus, these patients are at high risk for hypernatremia (Table 1).

Epidemiology of Hypernatremia

Given the powerful ability of thirst to defend against hypernatremia, it is not surprising that the incidence of this electrolyte disorder in patients presenting to the emergency department (ED) is uncommon (0.2%).1 Most of these outpatients usually have either chronic or acute impairment in their mental status (such as dementia). In critically ill patients, the incidence of hypernatremia is 10-fold higher (2-6%).2,3 Importantly, a large percentage of patients develop hypernatremia during the course of their hospital stays (especially in the ICU – up to 10%).4,5 The reasons for this are multi- fold and include:

  • Use of hypertonic fluids
  • Ongoing loss of body fluid loss (gastric decompression, stool, ostomy, fistulas, biliary drains, etc., inattention to water intake and needs)
  • Use of diuretics, lactulose
  • Poorly controlled hyperglycemia.6

Consequences and Complications Associated with Hypernatremia

The clinical symptoms associated with hypernatremia are alterations in central nervous system functioning, including a spectrum ranging from mild confusion to stupor and coma. These symptoms likely result from changes in cellular volume as water moves from the intracellular compartment to the more hypertonic extracellular compartment resulting in cell shrinkage.7

Mortality rates in patients with hypernatremia, especially those in the ICU, are very high (ranging from 15 to 50%), depending upon the severity of the hypernatremia.8,9 While hypernatremia has an independent effect on increased mortality, the underlying disease processes driving the development of hypernatremia is more likely to blame with the higher mortality rates.10

Etiology of Hypernatremia

Broadly speaking, the causes of hypernatremia can be divided into three categories:

  • water with solute loss (with water losses in excess of solute losses)
  • pure water losses
  • solute (sodium) gain.11

In those cases of water with solute loss and pure water losses, most patients will have impaired mental status and decreased thirst sensation, or the inability to obtain free water (see Table 2).

Correction of Hypernatremia

As many patients with hypernatremia will be volume depleted as well as dehydrated, assessing the need for rapid resuscitation is critical, and if needed, intravenous isotonic solutions should be administered until the patient is hemodynamically stable. Before correction of hypernatremia, it is vital to determine if the rise in serum sodium is acute (< 48 hours) or more chronic (> 48 hours). This is because with chronic hypernatremia, brain adaptations in cellular volume have occurred such that rapid correction in these circumstances can result in cerebral edema, increased intracranial pressure and brain stem herniation with death.12 In chronic states of hypernatremia the serum sodium should not be lowered by more than 8 to 10 mmol/L/24 hours. If it is unclear as to the duration of hypernatremia, it is best to assume that the condition is chronic and use a slower rate of correction.

Several formulas are available to determine the rates of infusion of hypotonic solutions and any of these can be utilized.7,13,14 However, it is critical that the clinician measure serum sodium levels frequently the duration of correction (every 4-6 hours), so that over- rapid correction is avoided and infusion/replacement rates for water can be adjusted. Water replacement can be achieved in several manners: (1) intravenous hypotonic fluids which may range from 0.45% saline to 5% dextrose in water or (2) enteral water administration.

In many cases, it is important to recognize that the free water deficit may be great and along with continuing water losses (insensible losses), the replacement rates can be substantially greater than 1-2 liter per day. When replacement rates are greater than 1 liter in a 24 hour period, administering water replacement only via the gastrointestinal route may prove challenging as the following cases highlight.

CASE 1

46 year-old female who is post-repair of a congenital heart defect is now requiring mechanical ventilation. A percutaneous gastrostomy (PEG) tube is in place and the patient is tolerating enteral nutrition (EN) with a daily volume of 1400 ml of enteral formula. Over the past few days, she has become hypernatremic and the care team increased her water flushes to 300mL every 4 hours (1800mL per 24 hours) to address her estimated water deficit. Thus, in total, she was receiving 3200 ml of fluid enterally per day. In this case, she became quite uncomfortable and given this concern as well as concerns for gastric distention and risk for aspiration, it was recommended she be given IV replacement of her free water deficit and minimize enteral delivery to only tube feeding and necessary medications until the distension resolved. Two days after the switch to IV free water replacement, her abdominal distention had resolved.

CASE 2

A 72 year-old male admitted to the intensive care unit (ICU) with sepsis developed severe diarrhea due to Clostridium difficile colitis. He is receiving enteral nutrition, but due to ongoing diarrhea and fluid losses he became hypernatremic. The patient was prescribed 400mL of water every 3 hours to replace the water deficit. With this increased fluid delivered enterally, he vomited leading to a change to IV water replacement.

Practical “Water Replacement”

The GI tract is normally capable of handling a large amount of fluids and solute/nutrient administration. However, in the setting of critical illness or serious GI problems (gastroparesis, etc.), this capacity for water and nutrient adsorption may be compromised and lead to increased abdominal distention, discomfort and the risk for nausea/vomiting and aspiration events. Water given the enteral route vs. the intravenous route is equally as effective; however there may be practical limitations to the use of the GI tract especially when replacement volumes are greater than 1000mL. On the other hand, IV water replacement is safe, reliable, predictable, consistent, and avoids these complications.

Oral versus IV Hydration

If the clinician is contemplating oral hydration, it is important to assess the ability of the GI tract to accommodate and absorb the additional fluid load. This is especially true if the patient is already receiving EN and the additional volume with hydration may prove intolerable. Certainly, if a patient is having trouble tolerating EN at the outset, then IV hydration should be the route of choice. Other key questions that need to be asked before utilizing enteral hydration include:

  1. Will enteral solutions be held for periods of time (such as for procedures, lost access)?
  2. Does the patient have impaired GI motility?
  3. Is the patient constipated?
  4. Is the patient at risk for aspiration that could be worsened by increased GI distention?

Finally, it should be noted that when large and frequent water flushes are ordered (such as 300mL every 4 hours), each time the flush is scheduled to run in, enteral feedings are stopped or automatically shut off (if the patient is on a dual pump), while the water infuses. The larger the flush, the more time it takes to run in. If the patient has frequent and large flushes, this can translate into significant lost feeding time and the patient?s nutritional status is compromised. Furthermore, if the above dual enteral pump is being used and the patient is on a nocturnal, or other cycled delivery mode, when the pump is turned off, no flushes will be infused.

Suggested Guidelines

  1. For serum sodium < 150 mmol/L, it is reasonable to try enteral water replacement up to 1 liter in divided doses (for example, 250mL every 6 hours, or 165mL every 4 hours).
  2. For serum sodium > 150 mmol/L, IV hydration should be given carefully, and in a controlled and reliable fashion, using dextrose 5% in water or another hypotonic fluid as appropriate for the individual patient.

Download Tables, Images & References

hacklinkJojobet Girişivermectin tabletMadridbetMadridbetMadridbetbaşakşehir masaj salonumeritbetanadoluslotCasibom GirişsuperbetinanadoluslotmeritbetsuperbetinTophillbetcasibomJojobet GirişcasibomCasibom GirişHoliganbetkavbetgalabetGamdomMarsbahisCasibomJojobetJojobet